CA2511840A1 - Anti-cancer medicaments - Google Patents

Abstract

Novel compounds and methods of using those compounds for the treatment of oncological conditions are provided. In a preferred embodiment, modulation o f the activation states of abl or bcr-abl .alpha.-kinase proteins comprises th e step of contacting the kinase proteins with the novel compounds.

Description

ANTI-CANCER MEDICAMENTS
BACKGROUND OF THE INVENTION
Related Applications This application claims the benefit of provisional applications entitled Process For MODULATING PROTEIN FUNCTION, S/N 60/437,487 filed December 31, 2002, ANTI-CANCER MEDICAMENTS, S/N 60/437,403 filed December 31, 2002, ANTI-INFLAMMATORY MEDICAMENTS, S/N 60/437,415 filed December 31, 2002, ANTI-INFLAMMATORY MEDICAMENTS, S/N 60/437,304 filed December 31, 2002, and MEDICAMENTS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS OR
DIABETES, S/N 60/463,804 filed April 18, 2003. Each of these applications is incorporated by reference herein.
Field of the W vention The present invention relates to novel compounds and methods of using those compounds to treat oncological conditions.
Description of the Prior Art Basic research has recently provided the life sciences community with an unprecedented volume of information on the human genetic code and the proteins that are produced by it. In 2001, the complete sequence of the human genome was reported (Larder, E.S. et al. Initial sequencing and analysis of the human genome. Nature (2001) 409:860; Venter, T.C. et al. The sequence of the human genome. Science (2001) 291:1304). Increasingly, the global research community is now classifying the 50,000+ proteins that are encoded by this genetic sequence, and more importantly, it is attempting to identify those proteins that are causative of major, under-treated human diseases.
Despite the wealth of information that the human genome and its proteins are providing, particularly in the area of conformational control of protein function, the methodology and strategy by which the pharmaceutical industry sets about to develop srriall molecule therapeutics has not significantly advanced beyond using native protein active sites for binding to small molecule therapeutic agents. These native active sites are normally used by proteins to perform essential cellular functions by binding to and processing natural substrates or tranducing signals from natural ligands. Because these native pockets are used broadly by many other proteins within protein families, drugs which interact with them are often plagued by lack of selectivity and, as a consequence, insufficient therapeutic windows to achieve maximum efficacy. Side effects and toxicities are revealed in such small molecules, either during preclinical discovery, clinical trials, or later in the marketplace. Side effects and toxicities continue to be a major reason for the high attrition rate seen within the drug development process.
For the lcinase protein family of proteins, interactions at these native active sites have been recently reviewed:
see J. Dumas, Protein Kinase Inhibitors: Emerging Pharmacophores 1997-2001, Expert Opinion on Therapeutic Patents (2001) 11: 405-429; J. Dumas, Editor, New challenges in Protein Kinase W hibition, in Curre~zt Topics in Medicinal Clzemistr~ (2002) 2: issue 9.
It is known that proteins are flexible, and this flexibility has been reported and utilized with the discovery of the small molecules which bind to alternative, flexible active sites with proteins. For review of this topic, see Teague, Nature ReviewslDrugDiscovery, Vol. 2, pp. 527-541 (2003). See also, Wu et al., Structure, Vol. 11, pp. 399-410 (2003).
However these reports focus on small molecules which bind only to proteins at the protein natural active sites. Peng et al., Bio. Organic andMedicinal ChenaistfyLtrs., Vol. 13, pp. 3693-3699 (2003), and Schindler, et al., Science, Vol. 289, p. 1938 (2000) describe inhibitors of abl lcinase.
These inhibitors are identified in WO Publication No. 2002/034727. This class of inhibitors binds to the ATP active site while also binding in a mode that induces movement of the kinase catalytic loop. Pargellis et al., Nature Structural Biology, Vol. 9, p. 268 (2002) reported inhibitors p38 alpha-kinase also disclosed in WO Publication No. 00/43384 and Regan et al., J. Medicinal Chenaistfy, Vol. 45, pp. 2994-3008 (2002). This class of inhibitors also interacts with the kinase at the ATP active site involving a concomitant movement of the kinase activation loop.
More recently, it has been disclosed that kinases utilize activation loops and lcinase domain regulatory pockets to control their state of catalytic activity. This has been recently reviewed (see, e.g., M. Huse and J. Kuriyan, Cell (2002) 109:275).
SUMMARY OF THE INVENTION
The present invention is broadly concerned with new compounds for use in treating anti-inflammatory conditions and methods of treating such conditions. In more detail, the inventive compounds have the formula ~Ri--~X~A~N)-D--~L~--E--~Y~Q
wherein:
R' is selected from the group consisting of aryls (preferably C~-C,$, and more preferably C~ C12) and heteroaryls;
each X and Y is individually selected from the group consisting.of -O-, -S-, -NR~-, -NR~SOz-, -NR~CO-, alkynyls (preferably C1-C12, and more preferably C;-C~), alkenyls (preferablyCi-C~z, andmorepreferablyCl-C~), alkylenes (preferablyCl-CIZ, and more preferably C~-C6), -O(CHZ)h-,, and -NR~(CHZ)h , where each h is individually selected from the group consisting of l, 2, 3, or 4, and where for each of alkylenes (preferably C1-C,2, and more preferably C,-C6), -O(CHZ),,-, and -NR~(CHz)h , one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that with -O(CHZ),,-, the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic (preferably C~-CIB, and more preferably CG-C1z), monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrblyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of -C(O)-, -S(O)2-, -N(RG)CO-, -N(R~)SOz-, -N(RG)CON(R6)-;
jis0orl;
mis0orl;
nis0orl;
pis0orl;
qis0orl;
tis0orl;

Q is selected from the group consisting of R Ra O Ra Ra Ra Ra S N a O N O OQILiN
O N O , S N O O N O ~ O ~ /SO O I \ O
N /NwN / N % N
/N~S~ /N~S~ / N ~ \ , ~ R ~ \ >
_ a Ra a Q-1 ' ~ Q-2 ' Q-3Ra Q-4R Q 5 p Q GO
0 0 0 0~ ~o o ~
Ra Ra Ra ~
O N Ra Ra Ra /S\ /Ra ~~ / \N/S\N/R
O ~NRa NRa ~Z~H N Z H I
\ /N S~ /N > I , Ra >
R ~ o//\o Q-10 ~ Q-i l 1 ~ Q_7 O O O Ra Ra ~ Ra~N ORs Ra Ray \N~NH \N- -NH
N N N ~ ~ /
~ O
OR ~~l~O ~ Rs > ~ O
ORs ~ ~ ~OR6 Rs 1 fi RS
Rs .new ' .rvw 15 Q 12 Q_13 ' Q-14 Q 15 Q 16 Q 17 OH SH
O ww O' Ra\N O Na O ~ O COzH HO~p NI W W W \ W
Rs COa CN3 O
O CH N H3C CH3 J , , >
OR6 ~ , H3C H3C "l,L, 2O o H H H ~zR, O O\ %O R O O\ % Ra S=O O N~S/RB O N~N~S O
\ /
~N~S. ~ a N~S~Z N ~~~~ O O
O H H~ H ~ ~O O
W/\\W W ~W W ~W
~J ~ ~J ~ ~ ~ i ~ ~ ~~~
i i J
Q-24 ~_2g ~ ~ Q-27 Q-28 Q-29 O
N J

PI O N~ W
SOZN(Ra)z R9 I\OR6 Ra ~ (G k n Ra \ OR6 ~ ~ ~ O
/ ~ ~ ~ J , ~ J ~ ~ ~ and ~ ~ ;

each R4 group is individually selected from the group consisting of -H, alkyls (preferably C,-C,z, and more preferably C~-C~), aminoalkyls (preferably C1-C~z, and more preferably C~-C~), alkoxyalkyls (preferably C1-Clz, and more preferably C1-C~), aryls (preferably C6 C18, andmorepreferablyC~ Clz), aralkyls (preferablyCl-C~z, and more pr eferably C,-C6), heterocyclyls, and heterocyclylallcyls except when the R~ substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each RS is individually selected from the group consisting of -H, alkyls (preferably C~-C,z, and more preferably C1-C~), aryls (preferably C~ C18, and more preferably C~
C,z), heterocyclyls, alkylaminos (preferably C~-CIZ, and more preferably C~-C~), arylaminos (preferably C6-C18, and more preferably CG-CIZ), cycloalkylaminos (preferably C3-C,g, and more preferably CS-C,z and preferably C,-C,z, and more preferablyCi-C~), heterocyclylaminos, hydroxys, alkoxys (preferably C,-C,z, and more preferably CI-C~), aryloxys (preferably CG C,B, and more preferably CG
C,z), alkylthios (preferably C1-C,z, and more preferably C,-CG), arylthios (preferably C~ C,$, and more preferably C~-C,z), cyanos, halogens, perfluoroallcyis (preferably C~-C,z, and more preferably CI-C~), allcylcarbonyls (preferably C1-CIZ, and more preferably C~-C~), and nitros;
each R~ is individually selected from the group consisting of -H, alkyls (preferably C1-Clz, and more preferably C~-C6), allyls, and (3-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls (preferably C~-Ctz, and more preferably C1-C~), aralkyls (preferably C~-C~z, and more preferably C~-C~), heterocyclyls, and heterocyclylalkyls;
each R~ group is individually selected from the group consisting of -H, -F, and alkyls (preferably C1-Clz, and more preferably C1-C~), wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
G is selected from the group consisting of -O-, -S-, and -N(R~)-;
lcis0orl;

each Z is individually selected from the group consisting of -O- and -N(R4)-;
and each ring of formula (I) optionally includes one or more of R~, where R7 is a noninterfering substituent individually selected from the group consisting of -H, alkyls (preferably C1-C~z, and more preferably C1-C~), aryls (preferably C~-C~B, and more preferably C~-C~2), heterocyclyls, alkylaminos (preferably C1-C,2, and more preferably C,-C6), arylaminos (preferably C~ C,B, and more preferably C6-C,2), cycloalkylaminos (preferably C3-C,B, and more preferably CS-C,2 and preferably CI-C,2, and more preferably C~-C6), heterocyclylaminos, hydroxys, alkoxys (preferably C1-C,2, and more preferably C1-C~), aryloxys (preferably C~-lp C,B, and more preferably C6-C12), alkylthios (preferably C1-CI2, and more preferably C~-C6), arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls (preferably C,-C 1z, and more preferably C I-C6), allcylsulfonyls (preferably C 1-C,2, and more preferably C1-C~), aminosulfonyls, and perfluoroalkyls (preferably C1-C1,, and more preferably C,-C~).
15 W a preferred embodiment, the stmcture is of formula (I) except that:
when Q is Q-3 or Q-4, then the compound of fornmla (I) is not Ph / ~ N ~ N~Ph NvN ~ ~ or ~ \N~NH
PhB ~ NHZ >
Ph when Q is Q-7, then the compound of formula (I) is not O
NH
8120 = 2.3-difluoro; 2,3,6-trifluoro; 2, fluoro, 3-chloro; 2-chloro,3-fluoro;
3-cyano~ 4-chloro \ ~ A' = substituted phenyl R12~ ~ / Y' = CO; -NHCO-~ -S02-~ -S02NH-; f=0 or 1 NH 8121 = substituted phenyl; oxazolyl; pyridyl; pyrimidyl; pyrazolyl;
imidazolyl or O
N H 8123 = H; 2.3-difluoro; 3,5-difluoro; 2-fluoro, 4-fluoro; 2-chloro, 2,4-dichloro; 3,4-dichlora; 3-fluoro;
4-chloro, 2-bromo; 3-bromo; 4-bromo; 4-iodo; 2-methoxy; 3-methoxy; 4-methoxy;
3,4-dimethoxy;
2 4-dbnethoxy; 2,5-dimethoxy; 3 4,5-trunethoxy; 3-CF3; 4-CF3; 3,5-di-CF3;
4-CF30-; 3-vitro; 4-vitro; 3-vitro-4-chloro; 2-methyl;
_I \ 3-methyl; 4-methyl; 3,5-dhnethyl; 4-iso-propyl; 3-methylthio; 3-CF3S-; 3-chloro-4-methoxy 8123 / NH 4-methylthio; 4-hydroxy; 4-methoxymethyl; 4-methylsulfonyl A' = substituted phenyl ' Y" = CO; ~0 or 1 ~i R122= substituted phenyl; oxazolyl; pyrimidyl Rl2z 15 when Q is Q-7, RS is -OH, Y is -O-, -S-, or -CO-, m is 0, n is 0, p is 0, q is 0, and E is phenyl, then D is not thienyl, thiazolyl, or phenyl;
when Q is Q-7, then the compound of formula (I) is not O Me p Me O NH ~ NH
N~ N~ H~ O
O /~O ReowN ~ O ~ N W
H H Rat Re2 /
S~ \ I ~ I
HN I / O I /
O
i O I \ , HN I \ , W I I i / / , or R80 is H, Me Rg2 is substituted phenyl 2 $ R81 is substituted phenyl when Q is Q-9, then the compound of formula (I) is not Me Phi ~O Me O ~N-Me N
O ~ / O
N \
CH v Ph ~ or HzN ( z)n ~ / , NC R16=H, methyl O
HO N~N~R~s ~N\
I' N ~ ~ Rye R'~O
~N
Rn , R17, R18 = alkyl R19 = H, alkyl when Q is Q-10, then the compound of formula (~ is not O O, O RI00=med~yl,ethyl 8101 = alkyl, amutoalkyl, aryl, arylalkyl, P'~ooX,~N.S~NH thienylalkyl, pyridinylalkyl, N-H pR~oo phthalimidylalkyl, alkoxycarbonylalkyl, \ alkoxycarbonylaminoalkyl, N ~ / arylalkenylalkyl,alkoxyalky,bydroxyalkyl, R~o~ arylaminocarbonyl, arylalkoxycarbonylaminoalkyl O v 8102 =phenyl, uidolylphenyl v=Oorl X'=O, NH
or OMe N~N O O O1 8103 = furyl, thienyl, phenyl MeO~N~N~N'S' ZO;a 7C"=CorS
H H ~X"~R~o3 a = 1 or 2 wherein there is a bond between Q and ~Rl---~X~A~N~-D--~L t~--E--~Y~

of formula (I), and when Q is Q-11, t is 0, and E is phenyl, then any R7 on E
15 llOt an o-allcoxy in relation to said bond;
when Q is Q-1 l, then the COlllpotllld of formula (I) is not i - P Ph NH-II-NH-II-O I \
I I
Pr-1 Ph or O p O
o ., Jj R1o5~N~S~N~NH 8104=methyl, ethyl H H Rl OS = alkyl, phenyl ~ ~ ORto4 8106=fluorine-substituted phenyl H
Rlos N ~
O
when Q is Q-15, then the compound of formula (I) is not HN ~ i HN
O~ ~ ~ ' Rto~ or O~ ~ ~ I \
H H H CH v I /
8107 = phenyl when Q is Q-16, then the compound of formula (I) is not O
~O
Ne ~ \NH
H
R =Me, OH N~O
ii2 H
O
O H O N II-Ph ~N ~ NH
N
NH HN
O
O
O
O N HN-II-Ph HN S
O
Me O
O N
NH-II /
N
S O HN
N
O \ Ph HN ~0 ~NH
///O
i0 H Ph O~N I I w HN HN

Ph NH O
rv '0 ' NH
H , N- 'O
H
O
~S 0 NS I ANN
H
or N"O
H
F
R~o$=OH, SH, NI-I2 R~o9 = hydrogen or one or more methoxy, hydroxy, halogen, vitro, dimethylamino, or furanyl Rtyo = substituted phenyl, furanyl Rtii=OH or CI
X3=O, NH
when Q is Q-17, then tile compound of formula (1~ is not n-Bu N
N ~
R ~ O O~ ~H~Rso 2s p Rzs R.,~ = alkyl ' R3o = H, t-Bu, benzoyl when Q is Q-21, then the compound of formula (~ is not HOZC
~O
~~'~N
IoI
Ph when Q is Q-22, then the compound of formula (~ is selected from the group consisting of Ra Ra NH-L~-(NH)P D-(NH)p-(A)q [(X)j-R~]m NH-L~-(NH)p D-(NH)p (A)G-[(X)j R~]m I /
/
O NH O
NH
.W
W .W
I W ~OH ' L~ - C(O) or S(OZ) R4 Ra j CO-(NH)p-D-(NH)P (A)q [(X)~ R~)]m I ~ D-(NH)p (A)p-[(X)~ R~)]m O NH O NH
W W ~ \ ' W~W
OI ' OH

CO-(NH)p-D-(NH)p-(A)q-[(X)j R1)]m R4 ~ D-(NH)P (A)G-[(X)j R1)]m O NH /
O NH
I~W
W ~OH ~ and 12 ~ 'W , W~OH

but excluding H O Ray O N I ~ Rss HN \ Rs~
O / . ~ ~ O / Ra ~ / R38 1137 = N(Me)2, \ N \ R35 \ N \ R3s mo~pholino OMe OH, H
H R34 = Me CI ~ I H R38 = H, CN, OMe, OH, HO / R3a R35 =-N(Me)2, morpholino /~ Me benzyloxy, phenyl, vitro meta or para- R3G = H, F HO meta or para- R39 = H, OH
R40 = H, F
R41=H, CI
O O ~O O
\ OMe HN I / HN I N NJ HN I \ Nw /~O a i / /
Me M /
O / ( 0 \ N \ \ N \ ~N \
1~ Il / H ~ ~ / H Me ' ~~/ H Me , and HO
HO meta or para- OH meta or para-I~H
HO ~neta or para-Me0 / N~NHMe Me0 \ ~ i_IN

\ N \

when Q is Q-23, then the compound of fornmla (I) is not R42 / (CH~)9Me I I
\ N \ ~ ~ I \ N~ \
,I
HS I / I i N \ I ~ \ ~ I \ N
H HS I / R42 - H~ Me' ' HS
,N
O~~O
\ o ~ NJ
I ~ \ N ~
CI
HS I ~ ~ HS I ~ H
CI t-Bu w N \ I , CI I /
HS I ~ O N v I c-Bu ~ ~ N ~ / H-H ~ I SH
or O v0 O
HS I ~ I ~ S
when Q is Q-24, Q-25, Q-26, or Q-31, then ZS ~R~--~X~ mA~N~-D--~L~--E--~Y~
is selected from the group consisting of R~
R~ R~
\ W ~ W~W O W~W O O
i A-~X-R1)m ~ \
H H ~ ~H A-(X-R~)m ~H~S~A-tX-R1)m H W N, H ' H N W N
O~N~~ A-iX-R~)m ' O ~ ,t'1~W N~A-(X-R~)m O~ ~~ A-tX-R1)m W / R7 ~ IWI~R7 , and HN W / R~
I
wherein each W is individually selected from the group consisting of -CH- and -N-; and O~N \S~ ~R4 ~ OSO -R4 HN~N \S N-R S 'Ra p=S'Z'R4 O,S-Z~Ra \ H R p H ' \ H RQ HN H N \ p' Ra \
/ > > *~
*~
J ' * ~-~ ~
Q-24 Q-25 Q-26 or Q-31 where ~ denotes the point of attachment to Q-24, Q-25, Q-26, or Q-31;
when Q is Q-31, then the compound of formula (I~ is not O o0 Oy0 S,N
CI \ CI HN I / H
/ N.N \ I
~N
CI O H CI
or O
O S O
~ N N
H I H H
NHS / N /
d o~ ~p when Q is Q-2~, then the compound of formula (I) is not h,e H .
w w ° R~N ~ \
II_ I ~ I ~ NH-II ~
R2~N ~ N~S~R~
° °
c cri y s-NMe 2 H

when Q is Q-32, then (R i--~X~A~--~N~--D--~L~R-E~' ~ m 9 P n is not biphenyl, benzoxazolylphenyl, pyridylphenyl or bipyridyl;

when Q is Q-32, then the compound of formula (n is not EIO- ~ -CHZ
\ ~ N NI \
OEt / / / , O Rtao RtaaO O Rt33 H R73a0~
R O N ~ O~~ SiN \
/ Rtaa H H
H H
Rtat ' ~ ' Ri3o= benzoyl, substituted phenylaminocarbonyl RI31 =CI, Br, SPh, benzoyl, phenylsulfonyl Ri32= subsituted phenylaminocarbonyl Me Riaa = I-I, CI OEt Ph R~3,y= H, alkyl, allyl, B-trimethylsilyletltyl Et0-P-C
~~ / / ~ \
CH=CH
\ CH=CH \ \ \ /
O EI
Ph~N / / H- II-OEt OEt F
CH-POaHz \ CHz O \
/ / , or Ph when Q is Q-35 as shown ZR4 ~ZRQ
~ tt ~~ k ~ a ~ \ \
Q-35 (pccra) Q-35 (nzetct) wherein G is selected from the grOllp consisting of -O-, -S-, and -NR4-, lc is 0 or 1, and a is l, 2, 3, or 4, then ~R1-EX~A~--~N~-D-~L~-E--EY~
m 9 P n t is selected from the group consisting of H
R~ N W~ N~AUX)J-Rtlm Wow ~ o~ ~~R
~N~N'A OX)J-Rtlm * ~
* H H ~ H
R7 0 ° N W\ N A_t(X)i-R,lm W ~ * W~ 7 W O R
~N~A-ItX)l-Rtlm ~ H
H o~ N ~W~ N ~A-t(X>i-R, l m R~ HN W /~R7 W~W O
~S~
* H A-tlX)i-R,lm R~ R~
W ~ W W~W W~W
I ~ I
~A-~tX)J-R~lm * ~ ~A-UX)l-R~lm ~A-UX)l-Rilm * , and except that the compound of formula (I) is not COZR~i Me \ COzH \ I Rya ph I ~ (CHzjnC02R7s Me I \ I ~ \
_ v ~Wa ~ / / , I / , R , 1 ~ meta.Para ' ~~N R7z 28.1 R73=-OCH2C02H R75=H, Et ~W4 H R71 = H, Me R72 = ihiazolyl, isoxazolyl R74 = oxazolyl, imidazolyl R~s.
R7G = H, NH2, N02 W4=N. CH imidazolyl,furyl 28.2 R73=C02Me a=0-I
R74= chloroPheuyl O-N CI
i \ / X~COzRn ~ \COzR~e v meta, Para Me ~ ph NH
O R77 = H, alkyl O ~ COZH
HN X3=OorCH= HN / ~ O O'' NH
R78 = H, alkyl \ H , /
~ ~ I ~ COzMe \ I NH
HN~ HNJ Nd O
Me Rss O / I O
N \ N \
Rss ( / H H I \ , / COZMe COzRss Me0 /
FaC I \ \ ~ O
Me0 ~ ~ ~ / COZRss \ I ~ / , ~ ~' , \ v I mela, Para / OMe O RGS = H, Et RGG = alkyl Me O / ~ O
Me0 H
-O~COxR~a~
Me0 \v/
meta, para Riao - H, t-Bu CI
0 ~ ~ O
Me0 Me0 ~ ' COxMe O N~ I
OMe \ N \
H
HZNYN / OMe H3C N N
N~ ~ \ I \ N O ~ / O
NHz / ~ CO~H
\ I H
R79=H, Me ' Or \ ~ . N /
COZR~9 O

In a preferred embodiment, RI is selected from the group consisting of 6-5 fused heteroaryls, 6-5 fused heterocyclyls, 5-6 fused heteroaryls, and 5-6 fused heterocyclyls. In a particularly prefelTed embodiment, Ri is selected from the gTOllp CO1151Stlllg of W~W ~W N I \
$ W W ff I
I . N N . N ~ .) , ~~~
N RZ ~ ~ , Y ~ O n p N O ' R3 ~nnn ~ R5 ~ ~ R5 \
W W W
O~ ~O , ~O , NYS , NYS , Ra N~N_Ra , /
R2 RZ p W ~ ~ R~ \ I / N ~ ~ ~ ~R5 i / N R2 R N / W R N N ~ rN\ N
R ~ ~ , and Ra each RZ is individually selected from the group consisting of -H, alkyls (preferably C~-C,2, and more preferably C,-CG), aminos, allcylaminos (preferably C,-C,z, and more preferably C,-CG), arylaminos (preferably C~-C,B, and more preferably C~
C~z), cycloallcylaminos (preferably C3-CAB, and more preferably CS-C,2 and preferably C,-C,z, and more preferably C1-C~), heterocyclylaminos, halogens, allcoxys (preferably C1-C~Z, and more preferably C,-C~), and hydroxys; and each R3 is individually selected from the group consisting of -H, alkyls (preferably C~-C,Z, and more preferably C,-C~), allcylaminos (preferably C~-C,2, and more preferably C,-C~), arylamiyos (preferably C~-C,B, and more preferably CG-C,2), cycloallcylaminos (preferably C~-C~,, and more preferably C,-C~), heterocyclylaminos, alleoxys (preferably C,-C,2, and more preferably C1-C~), hydroxys, cyanos, halogens, perfluoroallcyls (preferably C,-C,?, and more preferably C,-C~), allcylsulfmyls (preferably C,-C,~, and more preferably C,-C~), allcylsulfonyls (preferably C,-C,Z, and more preferably C,-C~), R~,NHSO,-, and -NHS OzRa.
In another embodiment, A is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrimidyl, thienyl, fiuyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofurallyl, benzothienyl, pyrazolylpyrimidinyl, imidazopyrimidinyl, and purinyl.
With respect to the methods of the invention, the activation state of a kinase is determined by the interaction of switch control ligands and complemental switch control pockets. One conformation of the lcinase may result fr0111 the switch control ligand's interaction with a particular switch control pocket Whlle allOther CO11f01111at1011 play result fr0111 the ligand's interaction with a different switch control pocket. Generally interaction of the ligand with one pocket, such as the "on" poclcet, results in the Icinase assuming an active conformation wherein the kinase is biologically active. Similarly, an inactive conformation (wherein the lcinase is not biologically active) is assumed when the ligand interacts with another of the switch control pockets, such as the "off' poclcet. The switch control pocket can be selected from the group COIISiStlllg Of Sllllple, C0111pOSlte alld C0111b111ed switch control pockets.
Interaction between the switch control ligand and the switch control pockets is dynamic and therefore, the ligand is not always interacting with a switch control poclcet. In some instances, the ligand is not in a switch control pocket (such as occurs when the protein is changing from an active conformation to an inactive conformation). hl other instances, such as when the ligand is interacting with the environment surrounding the protein in order to determine with Which switch control pocket to interact, the ligand is not 111 a 5WltCh COlltr0l pOClCet. Interaction of the ligand with particular switch control poclcets is controlled in part by the charge status of the amino acid residues of the switch control ligand. When the ligand is in a neutral charge state, it interacts with one of the switch control poclcets and when it is in a charged state, it interacts with the other of the switch control pockets.' For example, the switch control ligand may have a plurality of OH groups and be in a neutral charge state. This neutral charge state results in a ligand that is more lilcely to interact Wlth Olle Of tile SWItCh COlltr0l pOClCetS through hydr ogee boding between the OH groups and selected residues of the pocket, thereby resulting in whichever protein conformation r esults from that interaction. However, if the OH groups of the switch control ligand become charged through phosphorylation or some other means, the propensity of the ligand to interact with the other of the switch control pockets will increase and the ligand will interact with this other switch control pocket through complementary covalent binding between the negatively or positively charged residues of the pocket and ligand. This will result in the protein assuming the opposite COllfOr11at1011 aSSUllled Whell the ligand was in a neutral charge state and interacting with the other switch control poclcet.
Of course, the conformation of the protein determines the activation. state of the protein and can therefore play a.role in protein-related diseases, processes, and conditions. For example, if a metabolic process requires a biologically active protein but the protein's switch control ligand remains in the switch control pocket (i.e. the "off' pocket) that results in a biologically inactive protein, that metabolic process cannot occur at a normal rate. Similarly, if a disease is exacerbated by a biologically active protein and the protein's switch control ligand remains in the switch control pocket (i.e. the "on" pocket) that results in the biologically active protein conformation, the disease condition will be worsened. Accordingly, as demonstrated by the present 111Ve11t1011, selective modulation of the switch control pocket and switch control ligand by the selective administration of a molecule will play an important role in the treatment and control of protein-related diseases, processes, and conditions.
One aspect of the invention provides a method Of lllOdlllat111g the activation state of a lcinase, preferably abl or bcr-abl alpha-lcinase and including both the consensus wild type sequence and disease polylnolphs thereof. The activation state is generally selected from an upregulated or dowllregulated state. The method generally comprises the step of contacting the lcinase with a molecule having the general fornula (n. When such contact occurs, the molecule will bind to a particular switch control pocket and the switch control ligand will have a greater propensity to interact with the other of the switch control pockets (i.e., the unoccupied one) and a lesser propensity to interact with tile occupied switch control poclcet. As a result, the protein will have a greater propensity to assume either an active or inactive conformation (and consequenctly be upregulated or downregulated), depending upon which of the switch control pockets is occupied by the molecule. Thus, contacting the lcinase with a molecule modulates that protein's activation state.. The molecule can act as all antagonist or an agonist of either switch control pocket. The contact between the molecule and the kinase preferably occurs at a region of a switch control pocket of the lcinase and more preferably in an interlobe oxyanion pocket of the lcinase. hl some instances, the contact between the molecule and the pocket also results in the alteration of the conformation of other adj acent sites and pockets, such as an ATP active site.
Such an alteration can also effect regulation and modulation of the active state of the protein.
Preferably, the region of the switch control pocket offhe leinase comprises an amino acid residue sequence operable for bllldlllg t0 the FOrlllllla I molecule. Sllch binding can occur between the molecule and a specific region of the switch control pocket with preferred regions including the a-C helix, the cx-D helix, the catalytic loop, the activation loop, and the C-terminal residues or C-lobe residues (all residues located downstream (toward the C-end) from the Activation loop), and combinations thereof. When the binding region is the ec-C helix, one preferred binding sequence in this helix is the sequence VEEFLKEAAVM, (SEQ ID NO. 2). When the binding region is the catalytic loop, one pr eferred binding sequence in this loop is HRDLAARNXL (SEQ
)D NO. 3). When the binding region is the activation loop, one preferred binding sequence in this loop is a sequence selected from the group consisting of DFGLSRLMT
(SEQ,JD N0.4), GDTYTAH (SEQ )D NO. 5), and combinations thereof. When the binding region is in the C-lobe residues, one preferred binding residue is F, found at position 416 relative to the full length sequence (residue 194 in SEQ )D NO. 1). When a biologically inactive protein conformation is desired, molecules which interact with the switch control pocket that norrrlally results in a biologically active protein conformation (when interacting with the switch control ligand) will be selected. Similarly, when a biologically active protein conformation is desired, molecules which interact with the switch control pocket that normally results in a biologically inactive prOtelll COllf01111at1O11 (When 111teTaCtlllg Wlth the switch control ligand) will be selected. Thus, the propensity of the protein to assume a desired conformation will be modulated by administration of the molecule. hl preferred forms, the molecule will be administered to an individual undergoing treatment for cancer including but not limited to chronic myelogeneous leukemia and stromal gastrointestinal tt11110TS. Ill StlCh fOrllls, it will be desired to select molecules that interact with the switch control pocket that generally leads to a biologically active protein conformation so that the protein will have the propensity to assume tile biologically inactive form and thereby alleviate the condition. It is contemplated that the molecules of the present invention will be administerable in any conventional form including oral, parenteral, inhalation, and 5t1bct1ta11eOt1S. It is preferred for the administration to.be in the oral form.
Preferred molecules include the preferred formula (I) compounds discussed above.
Another aspect of the present invention provides a method of treating cancer comprising the step of administering a molecule having the structure of the formula (I) compounds to the individual. SllCh COI1d1t1011S are Oftell the result of an overproduction of the biologically active form of a protein, 111Chldlllg 1C111aS8S. For example, a halhnarlc feattlr a Of C11TO111C 111yelOgelleollS
leukemia involves areciprocal ChrOl110SOlllal tTa11S10Cat1011111vOlVlllg htllllall ChTOn10SO1neS 9 and 22. This mutation fuses a segment of the bcr gene upstream of the second exon of the c-abl nonreceptor tyrosine lcinase gene. This fusion protein is called bcr-abl.
While the normal c-abl gene 'and its protein are tightly controlled in normal cells, the fusion protein product bcr-abl presents with elevated, constitutive kinase activity. It is this activity that enables bcr-abl fusion protein to transform cells and cause malignancy. ThllS, tile 111Velltloll discloses and utilizes small molecule inhibitors of bcr-abl kinase. These inhibitor s contain functionality which enable them to bind to an binding region, preferably an interlobe oxyanion regulator pocket in abl lcinase. The 111111b1tOT'S may alSO Colltalll fL111Ct1011a11ty WhlCh bllld t0 the ATP
pocket or other k111aSe a1111n0 acid residues taken from the N-lobe or C-lobe of the kinase.
The administering step generally includes the step of causing said molecule to contact a lcinase involved with elevated lcinase activity such as that found in cancer.
A particularly preferred kinase to contact is bcr-abl kinase. When the contact is between the molecule and a lcinase, the contact preferably occurs in a binding region (preferably an interlobe oxyanion pocket of the lcinase) that includes an amino acid residue sequence operable for binding to the Formula I molecule. Preferred binding regions of the interlobe oxyanion pocket include the a-C helix region, the catalytic loop, the activation loop, the C-terminal lobe or residues, and combinations thereof. When the binding region is the a-C helix, one preferred binding sequence in this helix is the sequence VEEFLI~EAAVM (SEQ ID NO. 2). When the binding region is the catalytic loop, one preferred binding sequence in this loop is HRDLAARNXL (SEQ ~ NO. 3).
When the binding region is the activation loop, one preferred binding sequence in this loop is a-sequence selected from the group consisting of DFGLSRLMT (SEQ ID N0.4), GDTYTAH
(SEQ ID NO. 5), and combinations thereof: A preferred residue with which to bind in the C-terminal lobe is F.
Such a method permits tr eatment of cancer by virtue of the modulation of the activation state of a lcinase by contacting the lcinase with a molecule that associates with the switch control pocket that nornlally leads to a biologically active form of the lcinase when interacting with the switch control ligand. Because the ligand cannot easily interact with the switch control pocket associated with or occupied by the molecule, the ligand tends to interact with the switch control pocket leading to the biologically inactive form of the protein, with the attendant result of a decrease in the amount of biologically active protein. Preferably, the cancer i selected from the group consisting Of C111o111C 111y1Oge11eol1S leukemia and stromal gastrointestinal tumors. As with the other methods of the invention, the molecules may be'administer ed in any coliventional form, with any conventional excipients or ingredients. However, it is preferred to administer the molecule in an oral dosage form. Preferred molecules are again selected from the group consisting of the preferred formula (I) compounds as discussed above.
BRIEF DESCRIPTION OF THE DRAWINGS
Figure 1 is a schematic representation of a naturally occurring mammalian protein in accordance with the invention including "on" and "off ' switch control pockets, a transiently modifiable switch control ligand, and an active ATP site;
Fig. 2 is a schematic representation of the protein of Fig. l, wherein.the switch control ligand is illustrated in a binding relationship with the off switch control poclcet, thereby causing the protein to assume a first biologically downregulated confornation;
Fig. 3 is a view similar to that of Fig. l, but illustrating the switch control ligand in its charged-modified condition wherein the OH groups of certain amino acid residues have been phosphorylated;
Fig. 4 is a view similar to that of Fig. 2, but depicting the protein wherein the switch control ligand is in a binding relationship with the on switch control poclcet, thereby causing the protein to assume a second biologically-active conformation different than the first conformation of Fig. 2;
Fig. 4a is an enlarged schematic view illustrating a representative binding between the phosphorylated residues of the switch control ligand, and complemental residues from the on switch control poclcet;
Fig. 5 is a view similar to that of Fig. 1, belt illustrating in schematic form possible small molecule compounds in a binding relationship with the on and off switch control pockets;
Fig. 6 is a schematic view of the protein in a situation where a composite switch control pocket is formed with portions of the switch control ligand and the on switch control poclcet, and with a small molecule in binding relationship with the composite poclcet; and Fig. 7 is a schematic view of the protein in a situation where a combined switch control pocket is formed with portions of the on switch control pocket, the switch control ligand sequence, and the active ATP site, and with a shall 11101eCLlle 111 binding relationship with the combined switch control pocleet.
DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
The present invention provides a way of rationally developing new small molecule modulators which interact with naturally occurring proteins (e.g., mammalian, and especially hlllllall proteins) in order to modulate the activity of the proteins. Novel protein-small molecule adducts are also provided. The invention preferably malces use of naturally occurring proteins having a conformational propel-ty whereby the pr oteins change their conformations ifZ vivo with a corresponding change in protein activity. For example, a given enzyme protein in one confornation may be biologically upregulated, while in another confornation, the salve protein may be biologically dowllregulated. The invention preferably malces use of one mechanism of conforllation change utilized by naturally occurring proteins, through the interaction of what are terned "switch control ligands" and "switch control pockets" within the protein.
As used herein, "switch control ligand" means a region or domain within a naturally OCCLi1T111g prOtelll alld haVlllg 011e Or 111OTe a1111110 aCld residues therein which are transiently modified ifz vivo between individual states by biochemical modification, typically ph05ph01'ylatlOll, sulfation, acylation or oxidation. Similarly, "switch control pocket".means a plurality Of COlltlgLlOllS Or 11011-COlltlg110115 alllln0 aCld residues within a naturally occurrnlg protein and comprising residues capable of binding ire. vivo with transiently modified residues of a switch control ligand in one of the individual states thereof in order to induce or restrict the conformation of the protein and thereby modulate the biological activity of the protein, and/or which is capable of binding with a non-naturally OCClIlTlllg switch control modulator molecule to induce or restrict a protein confornation and thereby modulate the biological activity of the protein.
A protein-modulator adduct in accordance with the invention comprises a naturally occurring protein having a switch control pocket with a non-natu r ally occurring molecule bound to the protein at the region of said switch control pocket, said molecule serving to at least partially regulate the biological activity of said protein by inducing or restricting the conformation of the protein. Preferably, the protein also has a corresponding switch control ligand, the ligand interacting i~z vivo with the pocket to regulate the conformation and biological aCtlVlty of the pr Otelll SLlCh that the pr otein will aSSllllle a f1r St COllfOl lllatl011 alld a f1r St biological activity upon the ligand-pocket interaction, and will assume a second, different conformation and biological activity in the absence of the ligand-pocket interaction.
The nature of the switch control ligand/switch control pocket interaction may be understood from a consideration of schematic Figs. 1-4. Specifically, in Fig.
1, a protein 100 is illustrated in schematic fOnl1 t0 lllchlde all "on" switch control poclcet 102, and "ofd' switch control pocket 104, and a switch control ligand 106. In addition, the schematically depicted protein also includes an ATP active site 108. In the exemplary pr otein of Fig. 1, the ligand 106 has three amino acid residues with side chain OH groups 110. The off pocket 104 contains corresponding X residues 112 and the on pocket 102 has Z residues 114. In the exemplary instance, the protein 100 will change its conformation depending upon the charge status of the OH groups 110 on ligand 106, i.e., when the OH groups are unmodified, a neutral charge is presented, but when these groups are phosphorylated a negative charge is presented.
The functionality of the pockets 102, 104 and ligand 106 can be understood from a consideration of Figs. 2-4. In Fig. 2, the ligand 106 is shown operatively interacted with the off pocket 104 such that the OH groups 110 interact with the X residues 112 forming a part of the pocket 104. Such interaction is primarilyby virtue of hydrogen bonding between the OH groups 110 and the residues 112. As seen, this ligand/poclcet interaction causes the protein 100 to assume a conformation different fr0111 that Seell 111 Fig. 1 and col~esponding to the off or biologically downregulated conformation of the protein.
Fig. 3 illustrates the situation where the ligand 106 has shifted from the off pocket interaction conformation of Fig. 2 and the OH groups 110 have been phospholylated, giving a negative charge to the ligand. In this condition, the ligand has a strong propensity to inter act with on poclcet 102, to thereby change the protein conformation to the on or biologically upregulated state (Fig. 4). Fig. 4a illustrates that the phosphorylated groups on the ligand 106 are attracted to positively charged residues 114 to achieve an ionic-like stabilizing bond.
Note that in the on conformation of Fig. 4, the protein conformation is different than the off conformation of Fig.
2, and that the ATP active site is available and the protein is functional as a lcinase enzyme.
Figs. 1-4 illustrate a simple situation where the protein exhibits discrete pockets 102 and 104 and ligand 106. However, in many cases a more complex switch control poclcet pattern is observed. Fig. 6 illustrates a situation when a an appropriate pocket for small molecule interaction is formed from amino acid residues taken both from ligand 106 and, for example, from pocket 102. This is termed a "composite switch control pocket" made up of.residues from both the ligand 106 and a pocket, and is referred to by the numeral 120. A small molecule 122 is illustrated which interacts with the pocket 120 for protein modulation purposes.
Another more complex switch poclcet is depicted in Fig. 7 wherein the pocket includes residues from on pocket 102, and ATP site 108 to create what is termed a "combined switch control pocket." Such a combined pocket is referred to as numeral 124 and may also include residues from ligand 106. An appropriate small molecule 126 is illustrated with pocket 124 for protein modulation proposes.
It will thus be appreciated that while in the simple pocket situation of Figs.l-4, the small molecule will interact with the simple pocket 102 or 104, in the more complex situations of Figs.
6 and 7 the interactive pockets are in the regions of the poclcets 120 or124.
Thus, broadly the the small molecules interact "at the region" of the respective switch control poclcet.

GENERAL SYNTHESIS OF COMPOUNDS
In the synthetic schemes of this section, q is 0 or 1. When q = 0, the substihlent is replaced by a synthetically non-interfering group R7.
Compounds of Formula I wherein D is taken from D-1 or D-2 and Y is alkylene are prepared according to the synthetic route shown in Scheme 1.1. Reaction of isothiocyanate 1 with chlorine, followed by addition of isocyanate 2 affords 3-oxo-thiadiazolium salt 3.
Quenching of the reaction with air affords compounds of Fornmla I-4.
Alternatively, reaction of isothiocyanate 1 with isothiocyanate 5 under the reaction conditions gives rise to compounds of Formula I=7. See A. Martinet et al, Journal ofMediciraal Clzenzist~y (2002) 45: 1292.
Intermediates 1, 2 and 5 are commercially available or prepared according to Scheme 1.2. Reaction of amine 8 'with phosgene or a phosgene equivalent affords isocyanate 2.
Similarly, reaction of amine 8 with thiophosgene affords isothiocyanate 5.
Amine 8 is prepared by palladium(0) catalyzed amination of 9, wherein Q is a group capable of oxidative insertion into palladium(0), according to methodology reported by S. Buchwald.
See M.
Wolter et al, Ocgaraie Letters (2002) 4:973; B.H. Yang and S. Buchwald, Journal of O~gai2ometallie Chemistry (1999) 576(1-2):125. In this reaction sequence, P is a suitable amine protecting group. Use of and removal of amine protecting groups is accomplished by methodology reported in the literaW re (Protective Groups in Organic Synthesis, Peter G.M.
Wutts, Theodora Greene (Editors) 3rd edition (April 1999) Wiley, John & Sons, Incorporated; ISBN: 0471160199): Starting CO111po1r11dS 9 are commercially available or readily prepared by one of ordinary skill in the art: See March's Advanced Organic Chemistry: Reactions, Mechanisms, and Structure, Michael B. Srlllth & Jeny March (Editors) 5th edition (January 2001) Wiley John & Sons; ISBN : 0471585890.

Scheme 1.2 ~NHz Phosgene N=C=O
[Rs02C-(NH)p]q-E-Y ~ [Rs02C-(NH)P]q-E-Y~
Base NH thiophosgene N=C=S
[R602C-(NH)p]q-E-Y~ 2 Base [Rs02C-(NH)P]q-E-Y~

8 _ R~O.,C-NHZ
R602C-NH-E-Y-NHP deprotect M-E-Y-N H P
Pd(0) catalysis ll g Compounds of Formula I wherein Q is taken from Q-1 or Q-2 and Y is alkylene are also available via the synthetic route shown in Scheme 1.3. Reaction of amine 8 with isocyanate or isothiocyanate 2a yields the urea/thiourea 8a which can be cyclized by the 5 addition of chlorocarbonyl sulfenyl chloride. See GB1115350 and US3818024, Revanlcar et.
al US Patent 4,093,624, and I~layman et. al JOC 1972, 37(10), 1532 for further details.
Where R4 is a readily removable protecting group (e.g. R = 3,4-d-methoxybenzyl amine), the action of mild, acidic deprotection conditions such as CAN or TFA will reveal the parent ring system of I-4 (X=O) and I-7 (X=S).

Scheme 1.3 X

X-O, S . Ra HN N
[R602C-(NH)plq-E-Y' NHZ
2a [R60aC-(NH)p]q-E-Y' H
8a, X=O, S
'X
CI
CI S~ ~N N'Ra Deprotection [R60zC-(NH)Plq-E-Y S
O
I-4 X=O
I-7 X=5 X
[R602C-(NH)Plq-E-Y~ S
1-4 X=O~\O
I-7 X=S
Compounds of Formula I wherein Q is taken from Q-1 or Q-2 and Y is -alkylene are also available as shown in Scheme 1.4. Condensation of isocyanate or isothiocyanate 2a with amine RSNHZ yields urea/thiourea 2b, which, when reacted with chlorocarbonyl sulfenyl chloride according to GB1115350 and US3818024 yields 2c. Where R4 is a readily removable protecting group (e.g. R = 3,4-d-methoxybenzyl amine), the action of mild, acidic deprotection conditions such as CAN or TFA will reveal the parent ring system of 2d.
Reaction of 2d with NaH in DMF, and displacement wherein M is a suitable leaving group t.: .
5LlCh aS ChIOTIde, bromide or iodide yields I-4 (X=O) and I-7 (X=S).
Scheme 1.4 R NCX R5NH2 R4HN N~RS CI~S~CI R4 N ~,RS Deprotection of Ra X=O, S
X
2a X=O, S X=O, S
2b 2c O O
HN ~, NaH/DMF
Rs - / ~ Rs CI [R602C (NH)plq-E-Y X
X=0, S [Re02C-(NH)p]q-E-Y' 2d I-4 X=O
8a I-7 X=S

COmpOLindS Of F01111111a I wherein Q is taken from Q-1' or Q-2' and Y is alkylene are available via the synthetic route shown in Scheme 1.5. Condensation of isocyanate or isothiocyanate 2a with ammonia yields urea/thiourea 2e, which, when reacted with chlorocarbonyl sulfenyl chloride according to GB1115350 and US3818024 yields 2f.
Reaction of 2f with NaH in DMF, and displacement wherein M is a suitable leaving group such as chloride, bromide or iodide yields yields I-4' ,(X=O) and I-7' (X=S).
Scheme 1.5 HN N 'CI S--~
R "
NH

~H CI
q S
3 ~ R4,N
NCX N~Fi R

4 ~
X_O ~
S

~
X X

2a X=O, S X=O, S

2e 2f O
S

NaH/DMF

N,R
/

a IRs02C-(NH)Plq-E-Y
~

CI X
[RsOZC-(NH)P)9-E-Y

1-4' X=O

8a 1-T X=S

Compounds of Formula I wherein Q is taken from Q-3 or Q-4 and Y is alkylene, are prepared according to the synthetic route shown in Schemes 2.1 and 2.2, respectively.
Reaction of 12, wherein M is a suitable leaving group, with the carbamate-protected hydrazine 13 affords intermediate 14. Reaction of 14 with an isocyanate gives rise to interniediate 15. Thermal cyclization of 15 affords 1,2,4-triazolidinedione of Formula I-16.
By analogy, scheme 2.2 illustrates the preparation of 3-thio-5-oxo-1,2,4-triazolidines of Formula I-18 by reaction of intermediate 14 with an isothiocyanate and subsequent thermal cyclization.

Scheme 2.1 O
~OR~o H2N-N \ Ra IRs~zC-(NH)PIq~E/Y~N~N OR~o [R60aC'(NH)Plq--E H
O
l2 Ra Ra N C O [RsO2C-(NH)p]q Y N OR~o heat ~E~ ~Ni ~ O
0i _NH
I
15 Ra Ra [RsOzC'(NH)Pjq ~ E /Y~ N, N
~O
1-16 ~N
O
Ra Scheme 2.2 Ra Ra-N=C=S [R602C'(NH)p]q-E~Y~N~N OR~o heat _14 O
17 S~NH
I
Ra [R60zC'(NH)PIq~E/Y~N~ /N
~ ~O
~N

Ra Intermediates 12 wherein p is 1 are readily available or are prepared by reaction of 19 with carbamates 10 under palladium (0)-catalyzed conditions. MI is a group which oxidatively inserts palladium(0) over group M. M~ is preferably iodo or bromo.
Compounds 19 are either commercially available or prepared by one of ordinary skill in the art.

Scheme 2.3 R602C-NHa E\ /M _ /E~. ~M
M~~ Y Pd(0) catalysis; Re~aCNH Y
1~ Base 12 C0111pO1111dS Of FOr111ll1a I wherein Q is taken from Q-3 or Q-4 and Y is alkylene are also prepared according to the synthetic route shown in Scheme 2.4. Oxidation of amine 5 R4NHz to the corresponding hydrazine, condensation with ethyl chloroformate subsequent heating yields1,2,4-triazolidinedione 15a. After the action of NaH in DMF, displacement wherein M is a suitable leaving group such as chloride, bromide or iodide yields I-16 (X=O) and I-18 (X=S).

10 Scheme 2.4 1. NaNOZ OII RSNCX
2. SnCh CI OEt ~pEt X-O, S heat R4NHz R4NHNH2 R4NHNH
2a O
HN~--~ . NaH/DMF (RsOzC-(NH)Plq-E-YvN~O
R4~N~N~Rs CI Ra N~N~Rs X [RsOzC-(NH)P)q-E-Y II~
X
15a 8a I-16 X=O
I-18 X=S
O O
HN-~ NaH/DMF ~-NH
,N NH _ (RsOzC_(NH)PJq-E-Y'-N~N~Ra Deprotection of Rs R4 ~ (RsO2C-(NH)p]q-E-Y
X
X 8a 15b I-16' X=O
I-18' X=S
Compounds of Formula I wherein Q is taken from Q-3' or Q-4' and Y is allcylene are also prepared according to the synthetic route shown in Scheme 2.4. When RS is a readily removable protecting group (e.g. R = 3,4-d-methoxybenzyl amine), the action of mild, acidic deprotection conditions such as CAN or TFA on 15a will reveal 1,2,4-triazolidinedione 15b.
After deprotonation of 15b by NaH in DMF, displacement wherein M is a suitable leaving group such as chloride, bromide or iodide yields I-16' (X=O) and I-18' (X=S).
Compounds of Formula I wherein Q is taken from Q-5 or Q-6 and Y is alkylene are prepared according to the synthetic route shown in Scheme 3. Reaction of hydrazine 20 with chlorosulfonylisocyanate and base, such as triethylamine, gives rise to a mixW
re of intermediates 21A and 21B which are not isolated but undergo cyclization iT~
sitar to afford compounds of Formulae I-22A and I-22B. Compounds I-22A and I-22B are separated by chromatography or fractional crystallization. Optionally, compounds I-22A and I-22B can undergo Mitsunobu ueaction with alcohols R40H to give compounds of Formulae I-23A and I-23B. Compounds 20 are prepared by acid-catalyzed deprotection of t-butyl carbamates of structure 14, wherein Rlo is t-butyl.
Scheme 3 R4 CIS02-N=C=O
[R602C-(HN)P]q-E-Y~N~NH
20 H Base [R60zC-(HN)P]q-E-Y~N~NH [R602C-(HN)P]q-E-Y~N~N O
H
pi 'NH NH
CI w ~
O~/S~CI O S ~

R
[R602C-(HN)P]q-E-YwN~N~ ,O [RsOzC-(HN)Plq-E-YwN~N4 O
SQO + O=S~N
/,'-NH ii Ph3P Ph3P
Diethyl azodicarboxylate Diethyl azodicarboxylate R~OH R40H
Ra Ra [R602C-(HN)P]q-E-YwN~N~s~O [R602C-(HN)P]q-E-YwN~N~O
// -N WO + ~'1 O ~ O-iS_N~

Compounds of Formula I wherein Q is Q-7 and Y is alkylene are prepared as shown in Scheme 4. Reaction of amine 8 with maleimide 24, wherein M is a suitable leaving group, affords compounds of Formula I-25. Reaction of compound 26, wherein M is a group which can oxidatively insert Pd(0), can participate in a Heck reaction with maleimide 27, affording compounds of Formula I-28. Maleimides 24 and 27 are commercially available or prepared by one of ordinary skill in the art.
Scheme 4 R4 O N

O \ N
[R602C-(NH)p]q-E-Y~ 24 R5 O
NHZ [R60zC-(NH)p]q-E-YEN ~
Base H R5 O N
Ra O O
O
[R602C'(NH)p]q~E\M 27 R5 [R60~C'(NH)p]q~E \
26 Pd(0), Base Rs Heclc Reaction 1-28 Compounds of Fornula I wherein Q is Q-8 and Y is alkylene are prepared as shown in Scheme 5, according to methods reported by M. Tremblay et al, .Journal of Combinatorial Claenzist~y (2002) 4:429. Reaction of polymer-bound activated ester 29 (polymer linkage is oxime activated-ester) with chlorosulfonylisocyante and t-butanol affords N-BOC
sulfonylurea 30. Subjection of 30 to the Mitsunobu reaction with R4OH gives rise to 31.
BOC-group removal with acid, preferably trifluoroacetic acid, and then treatment with base, preferably triethylamine, provides the desired sulfahydantoin I-32.
Optionally, intermediate 30 is treated with acid, preferably trifluoroacetic acid, to afford the N-unsubstituted sulfahydantoin I-33.

Scheme 5 R4 R4 CISO~-N=C=O
[R60~C-(NH)p]q-E-Y~NH pt-BuOH
t9~.;~

Ph P
[R602C-(NH)p]q-E-YEN Odiethyl azodicarboxylate D j~S~NH O R4OH
O
BOC

1) H+ R4 R4 [R6O2C-(NH)p]q-E-Yw i O~ _ [R602G_(NFi)P]q-E-Y~N
O~S~ ~R O 2) Triethylamine O\S\ O
31 /~ N 4 I-32 O N
BOC
Ra [Rs02C-(NH)plq-E-Y~N
O
H+ O,/S ~ N
30 o H

Compounds of Formula I wherein Q is Q-8 and Y is alkylene are also prepared as ShOWIl 111 Scheme 5.1. Ammc 8 is condensed with the glyoxal hemiester to yield 31a.
Reaction of chlorosulphonyl isocyanate first with benzyl alcohol then 31a yields 31b, which 5 after heating yields I-32.

Scheme 5.1 H~OEt O
H' ~
[R602C-(NH)p]q-E-Y~NHz O [R60zC-(NH)p]q-E-Y~N~OEt NaCHBH3 8 31a HzN~o~O O
1. ~ ~ OH ~N~
CISOZNCO (R602C-(NH)p]q-E-Y OEt 2. H O
' ~ 31b [RsOzC-(NH)p]q-E-Y~N v _OEt 31a 3. 5% Pd/C
O~S~N
N~O
heat [RsOzC-(NH)p]q-E-Y~

Compounds of Formula I wherein Q is taken from Q-8', are prepared according to the S SyllthetlC rOllte ShOWIl 111 Scheme 5.2. Formation of 31c by the lllethod of Muller and DuBois .JOC 1989, 54, 4471 and its deprotonation with NaH/DMF or NaH/DMF and subsequently alkylation wherein M is a suitable leaving group such as chloride, bromide or iodide yields I-32'. Alternatively, I-32' is also available as shown in Scheme 5.3. Mitsunobu reaction of boc-sulfamide amino ethyl ester with alcohol 8b (made by methods analogous to that for amine 8) yields 31c, which after Boc removal with 2N HCl in dioxane is cyclized by the action of NaH on 31d results in I-32'.
Scheme 5.2 O
O~S-NH
i NaN
p\~-NH
[R602C-(N H)pIq-E-Y ~ M [RsOzC-(NMplq-E-Y ~ N
8a 31c O
I-32' Scheme 5.3 H O (RsOzC-(NH)Plq-E-Y'OH
Boc-N~S~O O 8b [RsOzC (NH)Plq-E-Y N~~~O O
i HN
HN OEt DEADCAT, Ph3P' 31d OEt O
O~S-NH
heat [RsOzC-(NH)p]q-E-Y~N
O
I-32' Compounds of Formula I wherein Q is Q-9 and Y is alkylene are prepared as shown in Scheme 6. Reaction of polymer-bound amino acid ester 34 with an isocyanate affords intermediate urea 35. Treahnent of 3S with base, preferably pyridine or triethylamine, with optional heating, gives rise to compounds of Formula I-36.
Scheme 6 Ra R4 R4-N=C=O
(RsOZC-(NH)p]q-E-Y~ O
NH v~,, Ra R4 [R60zC-(NH)Plq-E-YwN OBase 35 ~,~'O
O~NH

Ra Ra [R60zC-(NH)p]q-E-YEN
O

Ra Compounds of Formula I wherein Q is Q-9 and Y is alkylene are also prepared as shown in Scheme 6.1. Reaction of aldehyde 8c (available by methods similar to that shown for 8a by anyone skilled in the art) with the t-butyl ester of glycine under reductive amination conditions yields 35a. Isocyanate 2a is condensed with p-nitrophenol (or the corresponding RQNHZ amine is condensed with p-nitrophenyl chloroformate) to yield the carbamic acid p-nitrophenyl ester, which when reacted with deprotonated 35a and yields the urea that when deprotected with acid yields 35b. Fonnula I-36 is directly available from 35b by the action of NaH and heat.
Scheme G.l 0 ~ ~ 0 HZNv 'Ot-Bu H\ ~fI
[R602C-(NH)Plq-E-Y~H ~ [R6p2C_(NH)Plq-E-Y~N~Ot-Bu NaCHBH3 8c 35a O. ~NOz 1. R4HN"O
2. I 2N HCI/Dioxane O N + O NHO
[R6O2C-(NH)pjq-E-Y~~O [R60~C-(NH)p]q-E-Y- '~OH
p6 35b ~OIIIpOLll1(1S Of FOrIlltila I Wherelll Q 1S taken from Q-9', are prepared according to the synthetic route shown in Scheme G.2. Fornlation of 35c by the method described in JP10007804A2 and Zvilichovsky and Zucker, Israel Journal of Chemistry, 1969, 7(4), 547-54 and its deprotonation with NaH/DMF or NaH/DMF and its subsequent displacement of M, wherein M is a suitable leaving group such as chloride, bromide or iodide, yields I-36'.
Scheme G.2 ~--NH
NaN O
-NH
[R60~C-(NH)Plq-CE-Y~M - [R60ZC-(NH)Pjq-E-Y~N
35c O
8a I-36' ~O111pOLllldS Of FOr111uIa I-39 wherein Q is Q-10 or Q-11, and Y is alkylene are prepared as shown in Schemes 7.1 and 7.2, respectively. Treatment of alcohol 37 (Z = O) or amine 37 (Z = NH) with chlorosulfonylisocyanate affords intermediate carbamate or urea of structure 38. Treatment of 38 with an amine of strucW re HN(R~)R4 and base, preferably triethylamine or pyridine, gives sulfonylureas of Fornmla I-39. Reaction of chlorosulonylisocyanate with an alcohol (Z = O) or amine (Z = NR4) 40 affords inteunediate 41. Treahment of 41 with an amine 8 and base, preferably triethylamine or pyridine, gives sulfonylureas of Formula I-42.
Scheme 7.1 C1502-N=C=0 O
[R60~C-(NH)Plq-E'Y~ZH [RsOaC-(NH)Plq-E-Yw ~ iSOzCI
Z N

H-N O\ /%
R4 [R60~C-(NH)Plq-E-Yw ~ iS~NiRa Base Z H
Ra Scheme 7.2 R4 H-Z O
~SO~CI
CISOz-N=C=O Z~N
H
_a~
[R602C'(NH)Plq-E-YwNiRS O 0 O
8 H Ray ~ iSl /Y-E-9f(NH)PC02Rs N
Base R5 GOIIIpOlIIIdS Of FOrlllllla I wherein Q is taken from Q-12 are prepared according to the synthetic route shown in Scheme 8. Readily available pyridine 43, wherein TIPS
is tri-iso-propylsilyl, is alkylated under standard conditions (KZG03, DMF, Rø-I or Mitsunobu conditions employing R4-OH) to give pyridine derivative 44 which is reacted with compound 12, wherein M is a suitable leaving group, to afford pyridones of formula I-45.

Scheme 8 Ra a TIPS
TI

Diethyl azodicarboxylate Ra O
[R602C-(N H)Plq-E-Yw M

- s O/ wN
Base Y-E-[(NH)pC02R6]q _I-_45 Compounds of Formula I wherein Q is taken from Q-13 are prepared according to the synthetic route shown in Scheme 9. Readily available pyridine 46 is alkylated under standard conditions (KZC03, DMF, Ra-I or Mitsunobu conditions employing Ra-OH) to give pyridine derivative 47. N-alkylation with K~C03, DMF, Ra-I affords pyridones of formula 48.
Intern~ediate 48'is partitioned to undergo a Heck reaction, giving I-49; a Buchwald amination reaction, giving I-51; or a Buchwald Cu(I) catalyzed O-arylation reaction, to give I-52. The Heck reaction product I-49 may be optionally hydrogenated to afford the saW
rated compound I-50. Wherein the phenyl ether Ra is methyl, compounds of formula I-49, I-50, I-51, or I-52 are treated with boron tribromide or lithium chloride to afford compounds of Formula I-53, wherein Ra is hydrogen.
R40, KZC03 DMFor Aceton or R OH, Ph P

Scheme 9 OH . ORa R RaO~ KzCOs R ORa DMFor Acetone ~ s R5 R41, K~C03 /
TIPSY ~ / or TIPSY ~ ~ DMF or Acetone ' O N CI O N CI
R40H, Ph3P O N CI
4~ Diethyl azodicarboxylate 47 R

ORa 48 E-[(N H )PC02Rslq R O Ra \-/ ~~ / ( 5 Hydrogenation / R5 48 / E-[(NH)pC02Rslq -' Heck reaction O R ,~ O N~(~'E-[(NH)pC02Rs]q Pd(0) a I-49 Ra n + 2 Base ORa _1-50 H2N~E-[(NH)pCO2Rs]q / R boron tribromide or lithium chloride boron tribromide n _ ~ or lithium chloride Buchwald aminatioo O N H nE-[(NH)pCO2Rs]q Pd(0) Ra 1-51 boron tribromide OH
Base - or lithium chloride / Rs HOE-[(NH)pCO~Rs]q ORa boron tribromide ~ ,E-[(NH)pCO~Rs]q qg n _ / R5 or lithium chloride O NR Y

Buchwald arylation Cu 1 O N~O~E-[(NH)pCOaRs]q I-53 () n Base Ra Compounds of Formula I wherein Q is taken from Q-14 are prepared according to the S SyllthetlC -rOllte ShOWIl 111 Scheme 10. Starting from readily avai]able pyridine 54, alkylation under standard conditions (I~2C03, DMF, R4-I or Mitsunobu conditions employing R4-OH) yields pyridine derivative 55. N-alkylation with K2CO3, DMF, R4-I affords pyridones of formula 56. Intermediate 56, wherein M is a suitable leaving group, preferably bromine or chlorine, is partitioned to undergo a Heck reaction, giving I-57; a Buchwald amination reaction , giving I-59; or a Buchwald Cu(I) catalyzed O-arylation reaction, to give I-60. The Heck reaction product I-57 may be optionally hydrogenated to afford the saturated compound I-58. Wherein the phenyl ether Ra is methyl, C0117pO1I11dS Of fOrlllllla I-57, I-58, I-59, or I-60 are treated with boron tribtomide or hthllllll ChlOrlde to afford Co111pOL1ndS
Of FOrllllla I-61, wherein R4 is hydrogen.

Scheme 10 OH ORa ORa O RaO, KzCOs O
\ DMForAcetone ~ \ O
R41, KZC03 TIPSY / R40H, Ph3P TIPSY / DMF or ACetoflB
O N R5 Diethyl azodicarboxylate O N RS

54 Ss - -- Ra oR4 s6 ORa E-[(NH)pCOzRs]q n + 2 \ ~1 E-[(NH)pCOZRs]q I3Ydr~ tion/ E-[(NH)pCO2Re]q s~ ~
I-Iecl< reaction O N"R5 Pd(0) Ra I-s7 o Ra R5 I-58 Base - -ORa HZN~E-[(NH)pCOZRs]q H BBr3 or LiCI
N~E-[(NH)pCO2R6]q BBr3 or LiCI
'~'n s6 ~n BBr or LiCI
Buchwald amination O Ra R5 3 OH
Pd(0) I-s9 ~ Y~E-[(NH)pCO2Re]q Base -HO E-[(NH)pC02R6]q ORa O N' _R

O~E-[(NH)pCO2R6]q BBr3 or LiCI a '~'n s6 "
Buchwald --arylatio» R I-G1 Cll(1) p Ra Base I-60 Compounds of Fornmla I wherein Q is taken from Q-15 are prepared according to the synthetic routes shown in Schemes 11 and 12. Starting esters 62 are available from the corresponding secoacids via TBS-ether and ester formation under standard conditions.
Reaction of protected secoester 62 with Meerwin's salt produces the vinyl ether 63 as a pair of regioisomers. Alternatively, reaction of 62 with dimethylamine affords the vinylogous carbamate 64. Formation of the dihydropyrimidinedione 66 proceeds by condensation with urea 65 with azeotropic removal of dimethylamine or methanol.
Dihydropyrimidinedione 66 may optionally be further substituted by Mitsunobu reaction with alcohols R40H
to give rise to compounds 67.
Scheme 12 illustrates the further synthetic elaboration of intermediates 67.
Removal of the silyl protecting group (TBS) is accomplished by treatment of 67 with flouride (tetra-n-butylammonium fluoride or cesium flouride) to give primacy alcohols 68.
Reaction of 68 with isocyanates 2 gives rise to compounds of Fornmla I-69. Alternatively, reaction of 68 with [R~OZC(NH)p]q-E-M, wherein M is a suitable leaving group, affords compounds of Formula I-70. Oxidation of 68 using the Dess-Mautin periodinane (D. Dess, J.
Martin, J. Ana.
Claena. Soc. (1991) 113:7277) or tetra-n-alkyl penithenate (W. Griffith, S.
Ley, Aldf°iclaimiccz Acta (1990) 23:13) gives the aldehydes 71. Reductive amination of 71 with amines 8 gives rise to compounds of Formula I-72. Alternatively, aldehydes 71 may be reacted with ammonium acetate under reductive allcylation conditions to give rise to the primary amine 73.
Reaction of 73 with isocyanates 2 affords compounds of Formula I-74.
Scheme 11 ~O O
O O Meerwin's TBSO \ O
Reagent ' OMe TBSO OMe - -n63 R5 R4F-IN 65 NI-h n R5 N(Me)2 O
Dimethylamit~ TBSO
62 4A sieves \- OMe n 64 Rs 66 RaOH
_66 Ph3P
diethyl azodicarboxylate Scheme 12 O
Raw ~ .Ra Ray ~ [R60zC-~H)P]q-E-N-C-O RawN~NH
N' _N N"NH 2 _ TBSO \ ~ HO \ (RsOzC (NH)p]q-C'NH\ /0 " \ O
O ~~ I~IO
Rs [RsOzC-MH)P]Q-E-M ~8 R 0 R

0 ~ Oxidation Ra~N~NH O O
,O \ Raw ~ [R~O20-(NI-I)p]q-E-NHZ ~
[RsOzC-(NH)Plq- n 0 N NH g Ra~N~NH
E
Rs OHO \ Reductive amination NH~~ ~r~0 n O [RsOzC-(NH)p]q-E n _71 Rs Rs ammonium acetate I-72 (reductive amination) O

~ [R60zC-(NI-I)Plq-R-N=C=O Raw N ~ N H
Ra~N~NH Z NH N \
[RsOzC-(NH)plq-E O ~~0 HZN ~~~~ n n 0 Rs Rs Compounds of Formula I wherein Q is taken fiom Q-16 are prepared according to the synthetic routes shown in Schemes 13 and 14. Starting esters 75 are available from the corresponding secoacids via TBS-ether and ester formation under standard conditions.
Reaction of protected secoester 75 with Meerwin's salt produces the vinyl ether 76 as a pair of regioisomers. Alternatively, reaction of 75 with dimethylamine affords the vinylogous carbamate 77. Formation of the dihydropyrimidinedione 78 proceeds by condensation with urea 65 with azeotropic removal of dimethylamine or methanol.
Dihydropyrimidinedione 78 may optionally be further substit<lted by Mitsunobu reaction with alcohols R40H to give rise to compounds 79. Compounds of Formulae I-81, I-82, I-84, and I-86 are prepared as shown in Scheme 14 by analogy to the sequence previously described in Scheme 12.

Scheme 13 \O O
Meerwin's _ Rs \ OMe O
O O II O
Reagent TBSO ~ n RaHN~NH2 R5 OMe ~6 65 R4~N NH
DimethylamirL N(Me)~J \
TBSO n 4A sieves R5 'O
R5 ~ OMe TBSO ~n TBSO ~n RdOH Ra~ ~ ~Ra N N
-_--Ph3P \ _ diethyl azodicarboxylate R5 'O
TBSO

Scheme l4 O
O R4\N " N/R4 R4\N~N~R4 RawN~N~Ra [~p2~-~H)pla-~-N=c=O \
\ 2 Rs ~~O ~ O
R \ O Rs \O
(~ I-8I n ~ H_E_[(NH)PCOzRsIG
\ TOH --OTBS 8~1 n 79 n [R~OaC-(NI-I)p]q-E-M
Oxidation O
O RawN~N~Ra O
RawN~N.Ra Raw ~ iR4 [~OzC gH)pl9-E-NI-Iz Rs \ O
N N
Reductive amination Rs \ O Rs \ O ~ n NH-E-[(NH)pCOzRsIG
I-g~ n O-E-[(NH)pC0 R 83 C CHO I 8ø O
z slG
_ n ammonium acetate R4wN~N~Ra (reductive amination) O Rs \ O
RawN~NiRa [RsOzC-(NH)P1Q-E-N°C-O ~ n NH
~NH-~-f(NH)PCOzRslq O
Rs \ O
nNHz I-86 Alkyl acetoacetates 87 are commercially available and are directly converted into the esters ~8 as shown in Scheme 15. Treatment of 87 with NaHMDS in THF, followed by quench with formaldehyde and TBSCI (n = 1) or M-(CH2)n-OTBS (n = 2-4) to give rise to compounds 88.
Scheme 15 O O O O
1. NaHMDS, THF
R5'~~OMe R5 OMe 2. CH,O duench;
87 or Q-(CH2)n-OTBS
~~ OTBS
88,n>1 O O
(for n = 1) R5 ~ ~OMe TBS-Cl, OTBS
pyridine, CHzCIz 88, n =1 I O COnlpOl111dS Of F011T1Lila I wherein Q is taken from Q-17 are prepared according to the synthetic routes shown in Schemes 16.1 and 16.2, and starts with the BOC-protected hydrazine 13, which is converted to the 1,2-disubstituted hydrazine 89 by a reductive alkylation with a glyoxal derivative mediated by sodium cyanoborohydride and acidic workup. Condensation of 89 with diethyl malonate in benzene under reflex yields the heterocycle 90. Oxidation with Nz04 in benzene (see Cardillo, Merlini and Boeri Gazz.
Cl~inz. Ital. (1966) 9:8) to the nitromalonohydrazide 91 and further treatment with PZOS in benzene (see: Cardillo,G. et al, Gazz. Clzini.Ital. (1966) 9:973-985) yields the tricarbonyl 92.
Alternatively, treatment of 90 with Brederick's reagent (t-BuOCH(N(Me2)Z, gives rise to 93, which is subjected to ozonolysis, with a DMS and methanol workup, to afford the protected tricarbonyl 92. Compound 92 is readily deprotected by the action of CsF in THF
to yield the primary alcohol 94. Alcohol 94 is optionally converted into the primary amine 95 by a sequence involving tosylate formation, azide displacement, and hydrogenation.

Scheme 16.1 O Noz I)~OTBS Et0 OEt O 0 BOC NaCNBI-1;, CH3CN OTBS~ \\~~ NzOg R4N-NHz --. R4HN-N~ O O RQN-N\ ~ R4N-N
13 Z) H+ H S9 ~p ~OTBS ~pTBS
_91 t-Bn0-CH(NMe)z)z FzO;
(Me)zN
Me0 OMe O I O oxonolysis O O
MeOH/DMS \~~~/~~
RqN N~OTBS RqN-N
~OTBS

CsF, THF
Me0 OMe t) tosyl chloride, base Me0 OMe O O _ 2) NaN
O~\~' i~0 RqN-N 3) hydrogenation ~NHa RQN-N
OOH
_94 Reaction of 94 with (hetero)aryl halide 26, wherein M is iodo, bromo, or chloro, under copper(I) catalysis affords compounds I-96. Optional deprotection of the di-methyl ketal with aqueous acid gives rise t0 C0111pOLl1ldS Of FOr111li1a I-98. By analogy, reaction of 5 amine 95 with 26 under palladium(0) catalysis affords compounds of Formula I-97. Optional deprotection of the di-methyl ketal with aqueous acid gives rise to compounds of Formula I-99.

Scheme 16.2 HO OH
Me0 OMe (RsO2C-(NH)P]q-E'M O~\~i~0 H , H., \O
O O Cu(I) base R4N NCO E N ~E [(NH)pCOzRs]q ~ -((NH)pCOzRs]q ~O
RdN-N ' OOH I-96 I-~8 HO OH
.M Me0 OMe Me0 OMe [R602C-(NH)p]q-E
O O 26 O's~~~~ H+, H.,O O O
R4N-N Pd(0),base RQN N~NH~E ((NH)pOOZRsI4 R4N N~NHiE-((NH)pCOzRslq ~NH~

9i --Compounds of Formula I wherein Q is taken from Q-17 are also prepared according to the synthetic route shown in Scheme 16.3. Deprotonation of 4,4-dimethyl-3,5-dioxo-pyrazolidine (95a, prepared according to the method described in Zinner and Boese, D.
PIZarniazie 1970, 25(S-6), 309-12 and Bausch, M. J.et.al J. Ong. Claeni. 1991, 56(19), 5643) with NaHIDMF or NaH/DMF and with NaH/DMF or NaH/DMF and its subsequent displacement of M, wherein M is a suitable leaving group such as chloride, bromide or iodide yields I-99a.
Scheme 16.3 O_~\ ~O HN
HN-NH
[R602C-( NH)Plq-E-Y'CI [RsO~C-(NH)Plq-E-Y ~ N
95a O
8a I-99a Compounds of Formula I wherein Q is taken from Q-18 are prepared as shown in Schemes 17.1 and 17.2. Aminoesters 100 are subjected to reductive alkylation conditions to give rise to intermediates 101. Condensation of amines 101 with carboxylic acids using an acid activating reagent such as dicyclohexylcarbodiimide (DCC)/hydroxybenzotriazole (HOBt) affords intermediate amides 102. Cyclization of amides 102 to tetramic acids 104 is . mediated by Amberlyst A-26 hydroxide resin after trapping of the i~z situ generated alkoxide 103 and submitting 103 to an acetic acid-mediated resin-release.

R5 .
Scheme 17.1 ~O
O R~CHO O RSCHZCO.,H O
_ ~NH~R4 R O~N~R4 .
RsO~NHz NaBH(OAc)3 Rs0 ~M'~ DCC, HOBt s M 102 100 ~'' 101 NMe3+ OH' ~ ~ O H+, R40H
-NMe3 O ~ R40 N ~ Ra ~~/ Ra M~ M
_104 M' is t-BuOCHz-, BOCNH(CHZ)3-M is HOCHZ-; HZN-(CHZ)a ;
BOCNH(CHZ)4-, HC=C-CHI 103 HZN-(CH2)4-; HC=C-CHZ
Scheme 17.2 illustrates the synthetic sequences for converting intermediates 104 to compounds of Formula I. Reaction of alcohol 104.1 with aryl or heteroaryl halide 26 (Q =
halogen) under copper(I) catalysis gives rise to compounds of Formula I-105.1.
Reaction of amines 104.2 and 104.3 with 26 under Buchwald palladium(0) catalyzed amination conditions affords compounds of Formulae I-105.2 and I-105.3. Reaction of acetylene 104.4 with 26 under Sonogashira coupling conditions affords compounds of Formula I-105.4.
Compounds I-105.4 may optionally be reduced to the corresponding saturated analogs I-105.5 by standard hydrogenation.

Scheme 17.2 Rs O Rs 0 fRsOzC-(NH)Plq-E~ M
Ra0 I 26 Ra0 I
N~Ra N~Ra OH Cu(I), base O~E_~(NH)pCO2Rs]q 104.1 1-105.1 Rs 0 O IRsOzC-(NH)Plq-E~M ' R40 ~ ~ 26 Ra0 N R
N~Ra ~ a Pd(0), base ( ) n ( )~~ NH~E-f(NH)PCOzRslq NHz 1-105.2, n = 3 104.2, n = 3 1-105.3, n = 4 104.3, n = 4 R IRsO2C-(NH)P1q-E~M Rs 0 Rs Q
s O 26 / hydrogenation R O
Ra0 ~ a ~ R4 Ra0 N R PdClz(Pb3P)z, CuI N~Ra ~ 4 Base (Sonogashira Coupling) E- NH CO R q(Rs02Cp(HN)]-E
f( )P z slq 104.4 I-105.4 I-105.5 Compounds of Fornmla I wherein Q is taken fi0111 Q-19, Q-20, or Q-21 are prepared as illustrated in Scheme 18. Commercially available Kemp's acid 106 is converted to its anhydride 107 using a dehydrating reagent, preferably di-isopropylcarbodiimide (DIC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC). Reaction of 107 with an amines R4NH2 affords the intermediate amides which are cyclized to the imides 108 by reaction with DIC or EDC. Alternatively, 107 is reacted with amines 8 to afford amides of Formula I-110.
Amides I-110 may optionally be further reacted with DIC or EDC to give rise to compounds of Formula I-111. Acid 108 is further reacted with amines 8 to give compounds of Formula I-109.

Scheme 18 co2H p o R4 0 COzH DIC or EDC HO~O O 1) R4NHz HO~ N
CO ~ ~'z H3C CH3 ~ O _ O
HsC CHa H3C CHa H3C 2) DIC or EDC

[R60zC-(NH)Plq HN O R4 O
[R602C-(NH)Pl4-EwNH ~ N

HsC CHs '- DIC, HOAt [R602C-(NH)P1G-EwNHz [RsOzC (NH)P19- \ [RsOzC-(NH)Plq-i O
NH O COZH DIC or EDC HO~O N
z 107 8 HsC CO CH3 ~ HsC O CH3 Compounds of Formula I wherein Q is taken from Q-22 or Q-23 are prepared as shown in Schemes 19.1 through 19.3. Preparation of intermediates 113 and 114 are prepared as shown in Scheme 19.1 fiom di-halo(hetero)aryls 112, wherein MZ is a more robust leaving group than M,. Reaction of 112 with amines 37 (Z = NH) either thermally in the presence of base or by palladium(0) catalysis in the presence of base and phosphine ligand affords compounds 113. Alternatively, reaction of 112 with alcohols 37 (X = O) either thermally in the presence of base or by copper(I) catalysis in the presence of base affords CO111pOLIIIdS 114.

Scheme 19.1 [R602C-(NH)PIq-E-Y~

w~w 3?,z=Ni-~ w~w M~~ Base [RsCzC-(NH)p]q-E-YEN
H
112 113.
M~
[R60~C-(N H)P]q-E-YyZH w ~w 37, Z = O [R602C-(NH)P]q-E-Y~C ~ /

Base 114 Scheme 19.2 illustrates the conversion of intermediates 113 into compounds of Formula I-115, I-118, or 117. Treatment of 113 with aqueous copper oxide or an alkaline hydroxide affords compounds of Formula I-115. Alternatively, treatment of 113 with t butylmercaptan under copper(I) catalysis in the presence of ethylene glycol and potassium carbonate gives rise to 116 (see F.Y. ICwong and S. L. Buchwald, OJgc~raic Letters (2002) 4:3517. Treatment of the t-butyl sulfide 116 with acid affords the desired thiols of Fornula I-118. Alterlatively, 113 may be treated with excess ammonia under pressurized conditions to afford compound 117.

M~
Scheme 19.2 ~
W~W
[RsOzC-(NH)Plq-E-YwN
H

aq Cu0 t-BUSH excess NH3, or CuI, ICZC03 base KOH ethylene glycol OH ~ StBu ~ NHz W~W W~W W~W
[R602C-(NH)PI9-E-YvN ( / (R6p2C_(NH)Pl9-E-YwN . ~ / [R6o~C (NH)Plq-E-YwN ~ /
H H H

H+
SH
W' \ W
[R602C-(N H )Pl9-E-Yw N
H

Scheme 19.3 illustrates the conversion of intermediate 114 into compounds of Formula I-119, I-122, and 121, by analogy to the sequence described in Scheme 19.2.

M~
Scheme 19.3 W ~ W
R602C-(NH)P]q-E-Y~O I /

aq Cu0 t-BUSH excess NH3, or CuI base I<OH ICZC03 ethylene glycol OH StBu NHz W~W W~W W~W

RsOzC-(NH)P]q-E-Yw0 R60zC-(NH)P]q-E-Yw0 R60zC-(NH)Plq-E-Yw0 I / I / I /

H~
SH
W~W
RsOzC-(NH)P1q-E-Y~O

Compounds of Formula I wherein Q is taken from Q-24, Q-25, or Q-2G are prepared as shown in Scheme 20. Reaction of CO111pOLl1ldS I-115 or I=119 with chlorosulfonylisocyanate, followed by ira situ reaction with amines HN(R4)~
gives rise to compounds of Fornmlae I-123 or I-124. Reaction of compounds I-118 or I-122 with a peracid, preferably peracetic acid or trifluoroperacetic acid, affords compounds of Formula I-125 or I-126. Reaction of compounds 117 or 121 with chlorosulfonylisocyanate, followed by ira sitz~ reaction with amines HN(R4)z or alcohols R40H, affords compounds of Fornmlae I-127, I-128, I-129, or I-130.

Scheme 20 W~W W~N/ W~W

Rs02C-(NH)Plq-E-Y~Z ~ )P]q-E-Y~Z RsOzC-(NH)P1q-E-Y~Z
/ RsOzC-(NH ~ /

1-115, Z = NH I-118, Z = 117, Z = NH
119,2= NH O 121,2=O
1- O 1-122,2= -1) Chlorosulfonyl- . 1) Chlorosulfouyl-isocyauate isocyanate Peracetic acid HN(RQ)~ 2) HN(R~), 2) or R40H
_ O O O
R
O~ OSO ~R4 S03H HN~H\S/N~ a H Ra WJ~W W~W Ra R602C-(NH)Plq-E-Y~Z ~ / R60~C-(NH)Plq-E-Y. I /
Z
RsOzC-(NH)Plq- Y\Z / I-127, Z=NH
1-123, Z = NH I-125, Z = NH 1-128, Z = O
I-124, Z = O I-126, Z = O
O S o/ Ra HN H
W~W
RsO2C-(NH)P]q-E-Y~Z I
1-129, Z = NH
1-130,2=O
Compounds of Formula I wherein Q is taken from Q-27 are prepared as illustrated in Scheme 21. Reductive alkylation of thiomorpholine with aldehydes 131 affords benzylic amines 132, which are then subjected to peracid oxidation to give rise to the thiomoipholine sulfones -133 (see C. R. Johnson et eel, Tetnalzedr-ooa (1969) 25: 5649).
Intermediates 133 are reacted with amines 8 (Z = NHZ) under Buchwald palladium-catalyzed amination conditions to give rise to compounds of Formula I-134. Alternatively, compounds 133 are reacted with alcohols 8 (Z = OH) under Buchwald copper(I) catalyzed conditions to afford compounds of Formula I-135. Alternatively, intermediates 133 are reacted with alkenes under palladium(0)-catalyzed Heck reaction conditions to give compounds of Formula I-136.
Compounds I-1.36 are optionally reduced to the corresponding saturated analogs I-137 by standard hydrogenation conditions or by the action of diimide.

~O
Cg' N J N J -o Scheme 21 CH ]O
N peracid \ H \ oxidation \
NaBH(OAc)3 ~ ~/ ~ i/
/

M 133 ~S O O
o NJ
[R602C-(NH)PIG-E-YwNH~
O [Rs02C-(NH)Plq-E~ \

133 133 pd(0)~ ph3P, ~ ~/
Pd(0), phosphine, \ base base ~ , / [RsOzO-(NH)p]q-E~ I-13G
[R602C-(NH)p]q-E-Y-NH

-- reduction (hydrogenation or diitnide) [R602C-(NH)Plq-E-YwOH S ~ O
O //
133 8 N J N J 'O
Gu(I), base \
[R602C-(NH)Plq-E-Y-O ~ i/
I-135 (R602C-(NH)plq-E~ I-137 CO111pOLIndS Of FolTllllla I whereinQ is taken from Q-27 are also prepared as illustrated in Scheme 21.1. Aldehyde 8c is reductively aminated with ammonia, and the resultant amine condensed with divinyl sulphone to yield I-134. Intermediate 134a is also available by reduction of amide 8d under a variety of standard conditions.
Scheme 21.1 O

[R602C-(NH)Plq-E-Y~H [RsOzC-(NH)Plq-E-Y~NHz NaCHBH3 134a 8c Amide reduction 0~,~
i.e. LAH 5 [R602C-(N H )p]q-E-Y ~ N HZ
[R602C-(NH)p]q-E-YEN
8d SO
1~ 134 Gl More generally, amines 134c are available via the reduction of amides 134b as shown in Scheme 21.2 The moipholine amide analogues 134d and moipholine analogues 134e are also available as shown in Scheme 21.2 Scheme 21.2 R~R2NH
[R60zC-(NH)p]q-E-Y OH ~ [R602C-(NH)p]q-E-Y NR~R~
DIC coupling 8e 134b H

CN, Amide reduction pJ DIC coupling i.e. LAH

O

~ IRsCzC-(N
H)p]q-E-Y
~NR~ R2 [R60~C-(NH
)p]q-E-Y
N
~

134c 134d Amide reduction i.e. LAH

[Rso2C-(NH)p]q-E-Y~

134e COIIIpOL111dS Of FOl-lllllla I wherein Q is taken from Q-28 or Q-29 are prepared according to the sequences illustrated in Scheme 22. Readily available amides 138 are reacted with chlorosulfonylisocyanate to give intermediates 140, which are reacted i~z sitar with amines HN(R4)Z or alcohols R40H to afford compounds of Formulae I-141 or I-142, respectively. Alternatively, amides 138 are reacted with sulfonyl chlorides to give compounds of Formula I-139.

H N ,CI
N-Scheme 22 coNH2 O O 0 ~~Ra)z ar CISOZ-N=C=O ~ R40H
base [R~02C-(NH )Plq-E ~ Y [R602C-(NH)Plq-E ~ Y

Ra Ra I H O
,N.S N~Ra N~N~Ss O ~( II ~ 0 O II O
O O O O
[RsO~C-(NH)PlQ-ELY /
[R602C-(NH)Plq-E~ Y
T_I 41 T-142 Rs O HN-Sc0 O
R9SOZCl base _138 [R602C-(NH)P14-E ~ Y

Compounds of Formula I wherein Q is taken from Q-30 are prepared as shown in Scheme 23. Readily available N-BOC anhydride 143 (see S. Chen et al, J: Ani.
C7Zem. Soc.
(1996) 118:2567) is reacted with amines HN(R~)z or alcohols R~OH to afford acids 144 or 145, respectively. Intermediates 144 or 145 are further reacted with amines HN(R4)z in the presence of an acid-activating reagent, preferably PyBOP and di-isopropylethylamine, to give diamides -146 or ester-amides 147. Intermediate 145 is converted to the diesters 148 by reaction with an alkyl iodide in the presence of base, preferably potassium carbonate.
Intermediates 146-148 are treated with HCl/dioxane to give the secondary amines 149-151, which are then condensed with acids 152 in the presence of PyBOP and di-isopropylethylamine to glVe CO111pOL111dS Of F017mllla I-153.

N~Ra)z O
Scheme 23 Ho2C o 2(Ra)NC ' N(Ra)2 O 'N N
O~O~ HN(Ra)z 1)PyBOP,i-PrzNEt 146 BOC _144 BoC
N or R~OH O ORs 2) HN(Ra)z O OR
BOC HOz ~ ~ 2(Ra)NC

BOC - BOC
R6I, base R O C O~ORs s z ~NJ _148 BOC
HCI, dioxane p-X1 O\, N(Ra)z 2(Ra)NC ~'(~
N O OH
O ~ PyBOP, i-PrzNEt N 149 CO-Xz H
O ORs 2(Ra)NCO
[R602C-(NH)PlG-E~ ~// [RsOzC-(NH)P1q-E~Y N

_152 Xi, Xz are N(Ra)z ORs X~ is N(Ra)z, X2 is OR6 Rs02~
X X are OR ~N~151 t~ z s Fi Compounds of Formula I wherein Q is taken from Q-31 or Q-32 are prepared according to the sequences illustrated in Scheme 24. Treatment of readily available sulfenamides 154 with amines 37 (Z = NH), alcohols 37 (Z = O), or alkenes 37 (Z = -CH=CHz), gives rise t0 COnIpOL111dS Of FOnllllla I-155. Treatment of sulfenamides I-155 with iodosobenzene in the presence of alcohols RGOH gives rise to the sulfonimidates of Formula I-157 (see~D. Leca et al, Organic Letters (2002) 4:4093). Alternatively, compounds I-155 (Z
_ -CH=CH) may be optionally reduced to the sahirated analogs I-15G (Z = CHZ-CHZ-), which are converted to the corresponding sulfonimidates I-157.
Treatment of readily available sulfonylchlorides 154.1 with amines HN(R4)2 and base gives rise to compounds of Formula I-154.2.

Scheme 24 [R60zC-(NH)PIq-E-Y~ZH
37, Z = NH
Pd(0), phosphine, NH
base O'S~NH2 ~ORs PhI=O \
SONHz [R602C-(NN)p]q-E-Y~ \
ZH
37, Z= O I/i/ M ~ N [RspzC_(NH)Plq-E-Y-Z
M / Cu(I), base [RsOzC-(NH)p]q-D-E-Y-Z

_154 I-155 PhI=0 [RsOzC-(NH)P]q-E-Yy R60H, ZH
MeCN
37, Z = CH=CH2 Pd(0), phosphine, O~~S~NHz base Z = CH=CH- ~ i/
i Hydrogenation [RsOzC-(NH)p]q-E-Y-(CHz)z S02NHz S02N(RQ)z \ HN(R4)z \
~~/ -~ li/
i i [RsOzC-(NH)p]q-E-Y [R602C-(NH)p]q-E-Y
154.1 I-154.2 Compounds of Formula I wherein Q is taken from Q-33 are prepared as shown in Scheme 25. Readily available nitrites 158 are reacted with amines 37 (Z = NH), alcohols 37 (Z = O), or alkenes 37 (Z = -CH=CH2) to afford compounds of Formula I-159.
Compounds I-159 (wherein Z = CH=CH-) are optionally reduced to their saturated analogs I-160 by standard catalytic hydrogenation conditions. Treatment of compounds I-159 or I-160 with a metal azide (preferably sodium azide or zinc azide) gives rise to tetrazoles of Formula I-161.

Scheme 25 [RsOzC-(NH)P1q-E-YwZH
37, Z=NH
Pd(~), phosphine' N N
base N NH
CN
CN [RspzC_(NH)P]q-E-Yw ~3 ~ \
ZH ( ~i/
\ 3T Z - O /~/ [RspzC_(NH)Plq-E-Y-Z
[RspzC-(NH)P]q-E-Y--Z
i Cu(I), base I'I''~ I-161 M

[RspzC-(NH)P]q-E-YwZH MNj 37, Z = C H=C H 2 CN
Pd(~)> pbospbine, \
base Hydrogenation //
i [R602C-(NH)p]q-E-Y-(CHz)z Compounds of Formula I wherein Q is taken from Q-34 are prepared as shown in Scheme 26. Readily available esters 162 are reacted with amines 37 (Z = NH), alcohols 37 (Z = O), or alkenes 37 (Z = -CH-CHZ) to afford compounds of Foinzula I-163.
Compounds I-163 (wherein Z is -CH=CH-) are optionally converted to the sahmated analogs I-164 by standard hydrogenation conditions. CO111pOtI1ldS I-163 or I-164 are converted to the desired phosphonates I-165 by an Arbuzov reaction sequence involving reduction of the esters to ~benzy]ic alcohols, conversion of the alcohols to the benzylic bromides, and treatment of the bromides with a tri-alkylphosphite. Optionally, phosphonates I-165 are converted to the fluorinated analogs I-166 by treatment with diethylaminosulfiu trifluoride (DAST).

Scheme 26 CO~Rs Z = CH=CH-i/
Hydrogenation [RsOzC-(NH)P19-E-Y-(CHz)2 [RsOaC-(NH)Pl4-E-YwZH I-164 37, Z=NH 1) reduction to alcohol (LiBH4) Pd(0), phosphine, 2) CBr4, Ph3P
base 3) P(ORB)3 CO2Rs ORs COzRs I) reduction to alcohol s [R602C-(NH)P14-E-Y~ ~ ~ (LiBHd) P-OR
37 Z - O ZH ~/
[RsOzC-(NH)P19-E-Y-Z 2) CBr4, Ph 3P
Cu(I), base 3) P(ORs)3 i/

_1-163 [RsOaC-(NH)P)9-E-Y-Z
[R60zC-(NH)Pl9-E-YyZH

37, Z = CH=CH2 DAST
Pd(0), phosphine, base [R60~C-(N

Compounds of Formula I wherein Q is taken from Q-34 are also prepared as illustrated in Scheme 26.1. Intermediate 8a, wherein M is a suitable leaving group such as chloride, bromide or iodide, is >:efluxed with triethyl phosphite and the resulting phosphoryl intermediate saponified under mild conditions to yield I-165.
Scheme 26.1 O
[R60~C-(NH)p]q-E-Y~M 1. P(OEt)3 ~~\ OH
[R60zC-(NH)p]q-E-Y pH
$a 2. saponification I-165 C0111pOLI1IdS Of FOr111tt1a I wherein Q is taken front Q-35 are prepared according to Scheme 27. Readily available acid chlorides 167 are reacted with oxazolidones in the presence of base to afford the N-acyl oxazolidinones 168. Intermediate 168 are reacted with amines 37 (Z = NH), alcohols 37 (Z = O), or alkenes 37 '(Z = -CH=CHZ) to afford the N-acyl oxazolidinones of Formula I-169. Compounds I-169 (wherein Z is -CH=CH-) are optionally converted to the saturated analogs I-170 under standard hydrogenation conditions.
Scheme 27 [R60~C-(NH)p]q-E-Y~ZH
37, Z=NH
Pd(0), phosphine,I O
~O O N , 0 base HN O O N~ \'R4 COCI
\ R~ \ RQ [Rs0237( ~ )PIOE-YwZH
s/ base ~~~/ Cii(I), base [RsOzC-(NH)p]q-E-Y-Z
M M

[R6~~C-(NH)p]q-E-Y~
37, Z = CH=CHZ ZH hydrogenation (Z = CH=CH) Pd(0), phosphine, base O', -O
O N
Ra //
[R602C-(NH)P1q-E-Y-(CH2)2 Compounds of Formula I wherein Q is taken from Q-36 are prepared as illustrated in Schemes 28.1 and 28.2. Reductive alkylation of the t-butylsulfide substituted piperazines with the readily available aldehydes 131 gives rise to the benzylic piperazines 171.
Internzediates 171 are reacted with amines 37 (Z = NH), alcohols 37 (Z = O), or alkenes 37 (Z
- -CH=CHZ) to give compounds 172, 173, or 174, respectively. Optionally, inteumediates 174 are converted to the saturated analogs 175 under standard hydrogenation conditions. .

CHO HNVN~St-Bu N~NZSt_BU
Scheme 28.1 . \ NaBH(OAc)3 ~s ~/
M M

NU ~--St-Bu [RsOzC-(NH)Plq-E-Yy H NUN~St-Bu 37, Z = NH 37, Z = CFI=CHZ \
171 \ 171 Pd(0), phosphine,' ~ ~/ Pd(0), phosphine, 17d base [RsOzC-(NH)p]q-E-Y-NH 17~ base [RsOZC-(NH)p]q-E-reduction (hydrogenation or diimide) NON--~St-Bu [RsOzC-(NH)Plq-E-Yw \
171 37, Z O ZH I ~/ N~/N-~St-Bu Cu(I), base IRsOzC-(NH)p]q-E-Y-0 ~/ 175 [R602C-(NH)p]q-E-Y
Scheme 28.2 illustrates the conversion of intermediate t-butylsulfides 172-175 to the sulfonic acids, employing a two step process involving acid-catalyzed deprotection of the t-buiyl sulfide to the corresponding mercaptans, and subsequent peracid oxidation '(preferably with peracetic acid or trifluoroperacetic acid) of the mercaptans to the desired sulfonic acids of Formula I-176.
Scheme 28.2 _ n N~/N~St-Bu ] H+ N~--~N~-SOsH
2) peracid oxidation [R6p2C-(NH)p]q-E-Y-Z /
[R60zC-(NH)p]q-E-Y-Z

I ~ Z = NH, O, CH=CH, CH2-CH2 In some instances a hybrid bcr-abl kinase inhibitor is prepared which also contains an ATP-pocket binding moiety or an allosteric pocket binding moiety R]-X-A-D. The synthesis of moieties R~-X-A-D are conducted as shown in Scheme 29. Readily available intermediates 177, which contain a group M capable of oxidative addition to palladium(0), are reacted with amines 178 (X = NH) under Buchwald Pd(0) amination conditions to afford 179. Alternatively amines or alcohols 178 (X = NH or O) are reacted thermally with 177 in the presence of base under nuclear aromatic substiW tion reaction conditions to afford 179.
Alternatively, alcohols 178 (X = O) are reacted with with 177 under Buchwald copper(I) catalyzed conditions to afford 179. In cases where p = l, the carbamate of 179 is removed, preferably under acidic conditions when R~ is t-butyl, to afford amines 180.
In cases where p = 0, the esters 179 are converted to the acids 181 preferably under acidic conditions when R~
is t-butyl.
Scheme 29 R~-XH
M-A-(NH)p-D-(NH)p'-CO~R6 »$ R~X-A-(NH)p-D-(NH)p'-C02R6 heat or Pd(0) catalysis 179 H+ H+
R~X-A-(NH)p-D-NH2 R~X-A-(NH)p-D-CO~H
180 y 81 Another sequence for preparing amines or alcohols 180 is illustrated in Scheme 30.
Reaction of amines or alcohols 178 with nitro(hetero)arenes 182 wherein M is a leaving group, preferably M is fluoride, or M is a group capable of oxidative insertion into palladium(0), preferably M is bromo, chloro, or iodo, gives intermediates 183.
Reduction of the nitro group under standard hydrogenation conditions or treatment with a reducing metal, such as stannous chloride, gives amines 180.
Scheme 30 R~-XH
reduction M-A-(NH)p-D-N02 ~~g R~X-A-(NH)p-D-NO~ ~ R~X-A-(NH)p-D-NH2 ~ 82 heat or ~ g3 l 80 Pd(0) catalysis -In instances when hybrid bcr-abl kinase inhibitors are prepared, compounds of Formula I-184 wherein q is 1 may be converted to amines I-185 (p = 1) or acids I-186 (p = 0) by analogy to the conditions described in Scheme 29. Compounds of Formula I-184 are prepared as illustrated in previous schemes l.l, 2.1, 2.2, 3, 4, 5, 6, 7.1, 7.2, $, 9, 10, 12, 14, 16.2, 17.2, 18, 19.1, 19.2, 19.3, 20, 21, 22, 23, 24, 25, 26, 27, or 28.2.
Scheme 31 E Q
[R602C-(NH)plq~ ~Yi q=1 H+ H+
p=1 p=0 H N'E~Y~O HOzC~E\Y~Q
z Compounds I-184 are taken from schemes 1.1, 2.1, 2.2, 3, 4, 5, 6, 7.1, 7.2, 8, 9, 10 12, 14, 16.2, 17.2, 18, 19.1, 19.2, 19.3, 20, 21, 22, 23, 24, 25, 26, 27, 28.2 The preparation of inhibitors of Fornula I which contain an amide linkage -CO-NH-connecting the oxyanion pocleet blndlng moieties and the Ri-X-A-D moieties are shown in Scheme 32. Treatment of acids 18.1 with an activating agelit, preferably PyBOP
in the presence of di-iso-propylethylamine, and amines I-185 gives compounds of Formula I.
Alternatively, retroamides of Formula I are fornied by treatment of acids I-186 with PyBOP
in the presence of di-iso-propylethylamine and amines 1~0.

Scheme 32 NHz~E~y~O + (R1X)m-A-(NH)p-D-COZH pygop~ i_pr2NEt (R~X)m-A-(NH)p~D~N~E/Y.O
IOI
Compounds 1-185 taken Compounds I81 taken from scheme 31 from scheme 29 _Amides of F_or_m_u_la 1 (hybrid inhibitors, possessing oxyanion pocket-binding moiety Q and moiety Rt-X-A-(NH)p-D) E Q (R~X)m-A-(NH)PwD~N~EwYia HOZC~ ~Y~ + (R1X)m-A-(NH)p-D-NHZ pyBop, i-pr~NEt (IO
Compounds I-186 taken Compounds 18t1 taken from from scheme 31 schemes 29 or 30 Retroamides of Fornml~ I
(hybrid inhibitors, possessing oxyanion pocket-binding moiety Q and moiety R~-X-A-(NH)p-D) The preparation of inhibitors of Formula I which contain an urea linkage NH-CO-NH- connecting the oxyanion pocket binding moieties and R1-X-A-D moieties are shown in Scheme 33, Treatment of amines I-185 with p-nitrophenyl chloroformate and base affords carbamates 187. Reaction of 187 with amines 180 gives ureas of Formula I.
Scheme 33 NH ~E~Y~O P-nitrophenyl chloroformate O HN' 'y (R~X)m-A-(NH)p-D-NHZ
base Compounds 180 taken from E R
Compounds I-185 taken p2N ~ O schemes 29 or 30 from scheme 31 187 O
A H DWH~HiEwYiQ
(RiX)m/
P
_F_or_m_u_Ia 1 (hybrid inhibitors, possessing oxyanion Pocket-binding moiety D and moiety Rt-X-A-(NH)p-B) Alternatively, inhibitors of Fonnitla I which contain an urea linkage NH-CO-NH-connecting the oxyanion pocket binding moieties and the Rl-X-A-D moieties are prepared as shown in Scheme 34. Treahment of amines 180 with p-nitrophenyl chlorofonmate and base affords carbamates 188. Reaction of 188 with amines I-185 gives areas of Formula I.
Scheme 34 p ~ E~ ,Q
(R~X)m-A-(NH)p-D-NHz p-nitrophenyl chloroformate \ p~HN.E~N~A~(XR~)m NH Y
Compounds 180 taken from base schemes 29 or 30 D N ~ / ~ Compounds 1-185 taken a from scheme 31 p Q~Y E.N HN.D~(N~A~(XRym O
_F_or_m_ul_a 1 (hybrid inhibitors, possessing oxyanion pocket-binding moiety Q and moiety Ri-X-A-(NH)p-D) V. Biological assessment of abl and ber-abl kinase inhibitor.
A continuous spectrophotometric kinase assay is used, wherein the production of adenosine diphosphate is coupled to the oxidation of NADH and measured as a reduction in absorbance at 340nM. For details see: Barker, S.C. et al, Bioc7aenZistjy (1995) 34:14843; and Schindler, T. et al, Science (2000) 289:1938.
Abl kinase assay Activity of nonphosphorylated Abl kinase was determined by following the production of ADP from the kinase reaction through coupling with the pyruvate kinase/lactate dehydrogenase system (e.g., Schindler, et al. Science (2000) 2~9, 1938-1942).
In this assay, the oxidation of NADH (thus the decrease at A34on~,) was continuous measured spectrophometrically: The reaction mixture (200 yl) contained Abl kinase (3.7 nM. Abl-2 from decode), peptide substrate (EAIYAAPFAKKK, 0.5 mM), ATP (0.5 mM), MgCI~, (5 mM), pyruvate kinase (1G units), lactate dehydrogenase (26 units), phosphoenol pyruvate (1 111M), and NADH (0.28 mM) in 100 mM Tris buffer, pH 7.5. The reaction was initiated by adding ATP. The absorption at 340 nm was monitored continuously for 3 to 4 hours at 30 °C
on Polarstar Optima plate reader (BMG). Under these conditions, a turn over number (k°at) of 1.4 s-~ was obtained for the preparation of Abl kinase, which is similar to that (1.7 s 1) reported for the nonphosphorylated enzyme (Brasher and Van Etten, JBC (2000) 275, 35631-35637). No autophosphorylation of Abl was observed under these conditions since the rate is constant throughout the entire reaction time and presumably because the concentration of the enzyme used is below the critical level (~ 10 nM) needed for the autophosphorylation (Brasher and Van Etten, JBC (2000) 275, 35631-35637). These results ensure what we monitored was the activity of nonphosphorylated Abl kinase.
Percentage of inhibition in the presence of an inhibitor was obtained by comparison of reaction rate (or slope) with that of a control. ICSO value was calculated from a series of inhibition values determined at a range of concentrations of the inhibitor using Prism. The IC50 values for Gleveec and PD 180970 were found to be 76 and 24 nM, respectively, which are close to that reported (Schindler, et al. Science (2000) 289, 1938-1942).
Inhi Example 10 uM IC50, # uM

_ 36 20 -.
-37 ~10 ~

EXAMPLES
The following examples set forth preferred methods in accordance with the invention.
It is to be understood, however, that these examples are provided by way of illustration and nothing therein should be taken as a limitation upon the overall scope of the invention.
Reagents 6-methyl-N1-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine hydrochloride (Reagent AA) and 6-methyl-NI-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine hydrochloride (Reagent BB), N-Methyl-2-(methylcarbamoylmethyl-amino)-acetamide (Reagent CC), terephthalic acid monobenzyl ester (Reagent DD), 4-formyl-benzoic acid methyl ester (Reagent EE), 4-methyl-N-3-(4-(3-pyridyl)-pyrimidin-2-yl)-benzene-1,3-diamine hydrochloride (Reagent FF), [Boc-sulfamide] aminoester (Reagent GG) and 6-methyl-Nl-(4-rnorpholinopyrimidin-2-yl)benzene-1,3-diamine hydrochloride (Reagent HH) were synthesized according to literature procedures.
REAGENT AA
N\ /N \ NHZ,HCI
I s'TN I /
I\
To a solution of N (3-amino-4-methyl-phenyl)acetamide (Sg, 25 mrnol) in DMF (5 ml) was added 2-chloro-4-phenyl-pyrirnidine (4g, 35 mmol) and KI (O.Sg, 3 rnmol), which was stirred at 100 °C overnight, cooled to 10° C and added to H20 (100mL). The resulting mixture was extracted with CHZC12 (2x100 mL), the combined organic layers dried (Na2S04) and concentrated in vacuo. The residue was dissolved in conc. HCl (10 mL), stirred at 80°C
for 2h and concentrated in vacuo to yield 6-methyl-Nl-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine hydrochloride (4.Sg, 65%). 'H NMR (CDC13): 7.96 (m, 2H), 7.'50-7.47 (m, 1H), 7.47-7.41 (rn, SH), 7.26 (111, 2H), 2.21(s, 3H); MS (ESI) n~/e: 277 (M++1) REAGENT BB
NYN \ NHzHCi I ~ IN
To a solution of N-(3-amino-4-methyl-phenyl) acetamide (Sg, 25 mmol) in DMF (5 mL) was added 2-chloro-pyrimidine (3.8g, 33 mmol) and KI (O.Sg), which was stirred at 100 °C overnight, cooled to 10° C and added to HZO (100mL). The resulting mixture was extracted with CHZC12 (2x100 mL), the combined organic layers dried (Na2S04) and concentrated in vacuo. The residue was dissolved in conc. HCl (10 mL), stirred at 80°C for 2h and concentrated in vacuo to yield 6-methyl-Nl-(4-phenylpyrimidin-2-yl)benzene-1,3-diamine hydrochloride (3.75g, 75%). 1H NMR (CDC13): 8.36 (dd, J = 15.2 & 4.8 Hz, 2H), 7.46 (d, J = 2.4 Hz, 1H), 6.97 (d, J = 8.0 Hz, 1H), 7.26 (s, 1H), 6.67 (t, J =
4.8 Hz, 1H), 6.39 (dd, J = 8.0, 2.4, Hz, 1H), 2.20 (s, 3H); MS (ESI) m/e:~ 201 (M++1).
REAGENT CC
H
wN~N~Ni H H
To a solution of benzyl amine (l6.Sg, 154 mmol) and ethyl bromoacetate (51.5 g, 308 nnnol) in ethanol (500 mL) was added KZC03 (127.5 g, 924 mmol). The mixture was stirred at RT for 3h, was filtered, washed with EtOH, concentrated in vacuo and chromatographed to yield benzyl-methoxycarbonylmethyl-amino)-acetic acid ethyl ester (29.02g, 67%). 1H NMR
CDCl3) 8 7.39-7.23 (m, SH), 4.16 (q, J= 7.2 Hz, 4H), 3.91 (s, 2H), 3.54 (s, 4H), 1.26 (t, J=
7.2 Hz, 6H); MS (ESI): m/e: 280 (M++H).
A solution of (benzyl-methoxycarbonylmethyl-amino)-acetic acid methyl ester (7.70g, 27.6 mmol) in methylamine alcohol solution (25-30%, 50 mL) was heated to 50°C in a sealed tube for.3h, cooled to RT and concentrated in vacuo to yield 2-(benzyl-methylcarbamoylmethyl-amino)N-methyl-acetamide in quantitative yield (7.63 g).

(CDC13) b 7.35-7.28 (m, SH), 6.75(br s, 2H), 3.71(s, 2H), 3.20 (s, 4H), 2.81(d, J= 5.6 Hz, 6H)MS (ESI) m/e 250(M+H+) The mixture of 2-(benzyl-methylcarbarnoylmethyl-amino)N-methyl-acetamid (3.09g, 11.2 mmol) in MeOH (30 mL) was added 10% Pd/C (O.lSg). The mixture was stined and heated to 40°C under 40 psi HZ for l Oh, filtered and concentrated in vacuo to yield N-methyl-2-(methylcarbamoyhnethyl-amino)-acetamide in quantitative yield (1.76 g).
~HNMR(CDC13) 8 6.95(brs, 2H), 3.23(s, 4H), 2.79(d, J=4.8Hz, 6H), 2.25(brs, 1H); MS (ESI) n~/e 160(M+H+) REAGENT DD
O OH
O O

REAGENT EE
0 0~
I\
/
O H
REAGENT FF
H
N_"N \ NHa I ,N I /
/
\ N
REAGENT HH
N_"N \ NH2, HCI
I ~N~ I /
Co~
To a solution of N (3-amino-4-methyl-phenyl) acetamide (Sg, 41 mmol) in DMF (5 ml) was added 4-(2-chloro-pyrimidin-4-yl)-morpholine (8.1g, 40 mmol) and KI
(O.Sg, 3 inmol), which was stined at 100 °C overnight, cooled to 10° C
and added to H20 (100mL).
The resulting mixture was extracted with CHZClz (2x100 mL), the combined organic layers dried (Na2S04).and concentrated in vacuo. The residue was dissolved in conc.
HCl (10 mL), stirred at 80°C for 2h and concentrated in vacuo to yield 6-methyl-N1-(4-morpholinopyrimidin-2-yl)benzene-1,3-diamine hydrochloride (S.Og, 65%). 'H NMR
(DMSO-d6) : 8.00 (d, J= 7.2 Hz, 1H), 7.57 (brs, 1H), 7.36 (d, J= 8.4 Hz, 1H), 7.14 (dd, J =
8.4, 1.6 Hz, 1H), 6.65 (d, J= 7.2 Hz, 1H), 3.69 (s, 4H), 3.66 (s, 4H), 2.25 (s, 3H). MS (ESI) m/e: 286 (M++1).
EXAMPLE A

o~ so II
\ ~rS.H~N~
MeO
O
To a stirred solution of chlorosulfonyl isocyanate (3g, 21 mmol) in of CHZC12 (50 mL) at 0 °C was slowly added pyrrolidine (l.Sg, 21 mmol) while the reaction temperature was controlled between 0-5 °C. After being stirred for l.Sh, a solution of 4-Aminomethyl-benzoic acid methyl ester hydrochloride (4.7 g, 23 mmol) and triethylamine (6.4g, 63 mmol) in .

CHZCIZ (120 mL) was slowly added while the reaction .temperature was controlled between 0-5 °C. When the addition was completed, the reaction solution was awarmed to RT, stirred overnight, then poured into of 10% HCl (130 mL) saturated with NaCI. The organic layer was separated and the aqueous layer was extracted with Et20 (3x80 mL). The combined organic layers were dried (NaZS04) and concentrated in vacuo to yield the crude product, which was purified by column chromatography on a silica gel to yield pure pyrolidine carboxamide, N-[(4-carbomethoxybenzyl)amino]sulfonyl (3 g, 43% yield). 1H NMR (DMSO-d6) 87.70 (d, J
= 2.1 Hz, 2H), 7.28 (d, J = 2.1 Hz, 2H), 4.84 (s, 2H), 3.83 (s, 3H), 3:15 (m, 4H), 1.67 (111, 4H); MS (ESI) m/e: 342 (M++1).
EXAMPLE B

\ ~:~.~ ~N~
Ho a A solution of Example A (60 mg, 0.18 mmol) in THF (10 mL) was added to 3N LiOH
(10 mL) at RT, stirred overnight, acidified with 1 N HCI, and extracted with EtOAc. The organic layer was dried (Na2SO4) and concentrated to yield pyrolidine carboxamide, N-((4-carboxybenzyl)amino]sulfonyl (40 mg, 70% yield). 1H NMR (DMSO-d6) 812.87 (s, 1H), 10.01 (s, 1H), 7.88 (d, J=2.0 Hz, 2H), 7.33 (d, J=2.0 Hz, 2H), 6.90 (m, 1H ), 4.28 (s, 2H), 3.28 (m, 4H), 1.75 (m, 4H); MS (ESI) m/e: 327 (M++1).

oso~
\ H~ .~ NV
N~b I \ b /
,N ~ O
I
To a solution of Reagent AA (14 mg, 0.048 mmol) in anhydrous DMF (1 mL) was added Et3N (26 yL, 0.18 mmol) at RT. The reaction mixture was stirred for 5 min, followed by addition of Example B (12 mg, 0.038 mmol), EDCI (14 mg, 0.055 mmol) and HOBt (7.4 mg, 0.055 mml). The reaction mixture was stirred over night at RT. Removal of solvent in vacuo followed by preparative HPLC yielded pure Example 1 (16 mg, 76%). 1H NMR
(CD3OD) 8 8.32 (d, J = 5:6 Hz, 1 H), 8.24 (d, J = 7.2 Hz, 2H), 8.09 (d, J =
2.0 Hz, 1 H), 7.92 (d, J = 8.0 Hz, 2H), 7.60-7.40 (m, SH), 7.44 (d, J = 8.4 Hz, 2H), 7.36 (d, J =
8.4 Hz, 1H), 4.43 (s, 2H), 3.41 (m, 4H), 2.34 (s, 3H), 1.89 (m 4H); MS (ESI) m/e: 586 (M++1).

oso \ N~ ~H~N
N~. N \ N ~ ~ H
/ O
The title compound was synthesized following the procedure for the preparation of Example 1, utilizing Example B and Reagent BB. 'H NMR (CD30D) ~ 8.46 (d, J=
5.2 Hz, 2H), 7.97 (dd, J = 8.0, 2.0 Hz, 1 H), 7.91 (d, J = 8.0 Hz, 2H), 7:50 (dd, . J
= 8.0, 2.0 Hz, 1 H), 7.44 (d, J = 8.0 Hz, 2H), 7.3 3 (d, J = 8.0 Hz, 1 H), 6.92 (t, J = 4.2 Hz, 1 H), 4.43 (s, 2H), 3 .41 (m, 4H), 2.28 (s, 3H), 1.89 (m, 4H); MS (ESI) m/e: 509 (M++1).
EXAMPLE C

\ ~ ~.s.N~
Me0 To a stirred solution of chlorosulfonyl isocyanate (3g, 21 mmol) in 50 mL of CH~C12 (50 mL) at 0 °C was slowly added a solution of 4-aminomethyl-benzoic acid methyl ester hydrochloride (4.7g, 23 mmol) and triethylamine (6.4g, 63 mmol) in CHZC12 (120 mL) while the reaction temperature was controlled between 0-5 °C. After being stirred for l.Sh, pyrrolidine (1.5 g, 21 mmol) was slowly added while the reaction temperature was controlled between 0-5 °C. When the addition was completed, the reaction solution was allowed to warm to RT, stirred overnight, then poured into of 10% HCl (130 mL) saturated with NaCl.
The organic layer was separated and the aqueous layer was extracted with Et20 (3x80 mL).
The combined organic layers were dried (Na2S04) and concentrated to yield the crude product, which was purified by column chromatography on a silica gel to yield pure Example C (2.5 g, 35% yield). 'H NMR (DMSO-d6) 87.87 (d, J=2.1 Hz, 2 H), 7.28 (d, J=2.1 Hz, 2 H), 4.89 (s, 2 H) 3.82 (s, 3 H), 3.15 (m, 4 H), 1.68 (m, 4 H); MS (ESI) n~/e: 342 {M++1).

EXAMPLE D
\ ~~pvS:N
HO I ti/
O
The title compound using synthesized following the procedure for Example B
utilizing Example C. 'H NMR (CD30D) 87.98 (d, J=2.0 Hz, 2 H), 7.38 (d, J=2.0 Hz, 2 H), 4.41 (s, 2 H), 3.39 (m, 4 H), 1.87 (m, 4 H); MS (ESI) m/e: 327 (M++1).

° °s,o N N N I / H H N
I~N I/
I
The title compound was synthesized following the procedure for the preparation of Example 1 utilizing Example D and Reagent AA. 1H NMR (CD30D) 88.31 (m, 1H), 8.23 (d, J = 2.1 Hz, 2H), 8.06 (s, 1 H), 7.81 (d, J = 2.1 Hz, 2H), 7.62 (m, 1 H), 7.54 (m, 4H), 7.43 (d, J
= 2.1 Hz, 2H), 7.37 (d, J= 2.1 Hz, 1H ), 4.43 (s, 2H), 3.40 (m, 4 H), 2.33 (s, 3H), 1.89 (m, 4H); MS (ESI) m/e: 586 (M++1).

° °s,o N N N I / H~H/ \N~
I I/ o The title compound was synthesized following the procedure of the preparation of Example 1 utilizing Example D and Reagent BB. IH NMR (CD30D) b8.45 (br s, 2H), 7.96 (d, J = 4.0 Hz, 1 H), 7.90 (d, J =8.0 Hz, 2H), 7.50 dd, J = 8.0, 2.0 Hz, 1 H), 7.62 (m, 1 H), 7.43 (d, J= 8.4 Hz, 2H), 7.29 (d, J= 8.4 Hz, 1H ), 6.87 (t, J= 4.8 Hz, 1H), 4.43 (s, 2H), 3.40 (m, 4 H), 2.27 (s, 3H), 1.89 (m, 4H); MS (ESI) n~/e: 510 (M++1).
EXAMPLE D
\ wN~O
Me0 I / ~O( O

To a suspension of glycine ethyl ester hydrochloride (6.Og, 34 mmol) in anhydrous CHZCIz (34 mL) was added triethylarnine (3.4g, 34 mmol) followed by anhydrous magnesium sulfate (12.28, 102 mmol) and Reagent EE (6.Og, 34 mmol). After refluxing for 2h , the solid was filtered, washed with brine, dried (MgS04) and concentrated in vacuo to produce methyl 4-((E)-((t-butoxycarbonyl)methylimino)methyl)benzoate which was used without further purification (8.2g, 97% yield). IH NMR (CDC13) 8 8.30 (s, 1H), 8.07 (d, J=
8.4 Hz, 2H) 7.84 (d, J= 8.4 Hz, 2H) 4.34 (s, 2H) 3.91 (s, 3H) 1.49 (s, 9H).
EXAMPLE E

Me0 I ~ H O
To a solution of Example D (B.Sg, 30 mmol) in MeOH (80 mL) was slowly added solid NaBH4 (3.42g, 90 mmol) while the reaction temperaW re was controlled below 20 °C.
After stirring for 2h, the reaction was quenched with H20, extracted with EtOAc (3x100 mL) and the combined organic layers were washed with brine, dried (NaZS04), concentrated in vacuo. The residue was purified via flash column chromatography to yield methyl 4-(((t-butoxycarbonyl)methylamino)methyl)benzoate (6.SSg, 77% yield). 'H NMR (CDC13) ~ 7.98 (d, J = 8.4 Hz, 2H), 7.40 (d, J = 8.4 Hz, 2H), 3.90 (s, 3H,) 3.84 (s, 2H) 3.29 (s, 2H) 1.4G (s, 9H).
EXAMPLE F
w N~o Me0 ~ O~NH
O
To a solution of Example E (5.1 g, 18 mmol) in THF (80 mL) was added KZC03 (4.2g, mmol) and methyl-carbamic acid 4-nitro-phenyl ester (3.68, 18 mmol). After being stirred overnight, the resulting solid was filtered. After adding H20 and EtOAc to the filtrate, the 25 organic layer was separated and the aqueous layer was extracted with EtOAc (3x100 mL).
Tlie combined organic layers were washed with brine, dried (NaZS04), concentrated in vacuo and purified by flash chromatography to yield Example F (4.4g, 73%). 'H NMR
(CDC13) 8.01 (d, .I= 8.4 Hz, 2H) 7.35 (d, J= 8.4 Hz, 2H) 4.59 (m, 1H) 4.57 (s, 2H) 3.91 (s, 3H) 3.90 (s, 2H) 2.79 (d, J= 4.4 Hz, 3H) 1.43 (s, 9H).

EXAMPLE G

N N~' MeO I /
O O
To a suspension of NaH (0.28g, 7 mmol) in THF (80 mL) at RT was slowly added a solution of Example F (1.85g, 5.5 mmol) in THF (50 mL). After stirnng for 2h, the resulting solid was filtered. After adding water and EtOAc to the filtrate, the organic layer was separated and the aqueous layer was extracted with EtOAc (3x100 mL). The combined organic layers were washed with brine, dried (Na2S04), and concentrated in vacuo to yield methyl 4-((3-methyl-2,4-dioxoimidazolidin-1-yl)methyl)benzoate (1.3g, 90°J°). 'H NMR
(CDCl3) 8.03 (d, J = 8.4 Hz, 2H) 7.32 (d, J = 8.4 Hz, 2H) 4.62 (s, 2H) 3.90 (s, 3H) 3.73 (s, 2H) 3.08 (s, 3H).
EXAMPLE H

N N
HO I

To the solution of Example G (900 mg, 3.44 mmol) in MeOH (30 mL) was added .
cons. HCl (10 mL). The resulting solution was heated to reflux for lh, quenched with sahirated Na2C03 (100 mL), and extracted with CHZC12 (100 mL). After separation, the organic layer was washed with brine, dried (NaZS04), and concentrated in vacuo to yield 4-((3-methyl-2,4-dioxoimidazolidin-1-yl)methyl)benzoic acid as a yellow solid.
The cntde product was used without further purification.

I0' N~N
N
I ~N I / O °
To a solution of Example H (200 mg, 0.81 mmol) in DMF (10 mL) were added EDCI
(200 mg, 1.0 mmol), HOBt (150 lllg, l.5mmo1), NMM (0.5 mL) and Reagent BB (300 mg, 1.5 mmol). After being stirred at RT overnight, the solvent was removed under vacuum. The resulting residue was purifted by preparative HPLC to yield pure 4-((3-methyl-2,4-dioxoimidazolidin-1-yl)methyl)-N-(4-methyl-3-(pyrimidin-2-ylamino)phenyl)benzamide (20 mg). 1H NMR (DMSO-c~ b:10.14 (s, 1H), 8.87 (s, 1H),8.35 (d, J= 4.8 Hz, 2H), 7.91 (d, J=

8 Hz, 2 H), 7.84 (d, J = 1.6 Hz, 1 H), 7.45 (dd, J= 8.4, 2.0 Hz, 1 H), 7.41 (d, J= 7.6 Hz, 2H), 7.15 (d, J= 8.0 Hz, 1H), 6.75 (t, J= 4.8 Hz, 1H), 4.56 (s, 2H), 3.89 (s, 2H), 2.87 (s, 3H), 2.15 (s, 3H); MS (ESI) m/e: 431 (M++1).
EXAMPLE G

/ I , ~ N~N_ N~ ~ ~ ~ W
~N ~ / O O
The title compound was synthesized following the procedure for the preparation of Example 5 utilizing Example H and Reagent AA to yield N-(3-(4-phenylpyrimidin-ylamino)-4-methylphenyl)-4-((3-methyl-2,4-dioxoimidazolidin-1-yl)methyl)benzamide. 'H
NMR (CDC13 -d) 8:8.45 (s, 1H), 8.39 (d, J= 5.6 Hz, 2H), 8.19 (s, 1H), 8.08 (dd, J= 7.2 Hz, 2 H), 7.84 (d, J= 8.4 Hz, 2H), 7.32-7.46 (m, 5 H), 7.25-7.29 (m, 2H), 7.13-7.17 (m, 2H), 4.56 (s, 2H), 3.70 (s, 2H), 3.03 (s, 3H), 2.30 (s, 3H). Ms (ESI) m/e: 507 (M++1).
EXAMPLE I
-NH
~O
~ ~ N H
O O
/
To a solution of Reagent CC (O.GBg, 4.30 mmol) in dry CHZC12 (20 mL) under N2 were added NMM (2.70g, 27.2 ll1n101), HOBt (0.91g, 6.7 mmol), EDCI (1.26g, 6.6 nnnol) and reagent DD (l.Sg, 5.90 mmol): After being stirred at RT overnight, the solvent was removed under reduced pressure. The residual was washed with H20, saturated aqueous KZC03 and HZO to yield the white solid, which was dried in vacuo to yield benzyl 4-(bis((methylcarbamoyl)methyl)carbamoyl)benzoate (0.72 g, 42% yield). 'H
NMR(CDCl3) 88.74 (s, 1H), 8.10 (d, J= 8.4 Hz, 2H), 7.50 (d, J 8.4Hz, 2H), 7.46 (m, SH), 6.35 (s,lH), 5.37 (s,2H), 3.94 (d, J= 10.8 Hz, 4H) 2.89 (m, 6H); MS (ESI) m/e: 398 (M++1).

EXAMPLE J
-NH
~O
O ~ ~ N~NH
HO O //O
To a solution of Example I (0.73g, 1.84 mmol) in MeOH (30 mL) was added 10%
PdIC (200 mg). The reaction mixture was then stirred at amblent temperature Llllder 1 atmosphere of HZ fox 45 min. The reaction mixture was filtered, the solid washed with EtOH, and the combined organics concentrated in vacuo to yield 4-(bis((methylcarbamoyl)methyl)carbamoyl)benzoic acid (0.52g, 92% yield). IH NMR
(CDCl3) 89.16 (s, 1 H), 8.05 (d, J = 8.4 Hz, 2H), 7.49 (d, J = 8.4 Hz, 2H), 4.04 (d, .I = G Hz, 4H), 2.94 (m, GH); MS (ESI) m/e: 308 (M++1).

oo~y ~N
H
I N b I \ \ Nw ~N ~ O O
The title compound was synthesized following the procedure for the preparation of Example 1 utilizing Example ' J and Reagent BB to yield N1,N~-bis((methylcarbamoyl)methyl)-N4-(4-methyl-3-(pyrimidin-2-ylamino)phenyl)terephthalamide. 'H NMR (CD30D) 8 8.43 (d, J= 5.2 Hz, 2H), 7.98 (d, J=
8.4 Hz, 1H), 7.97 (s, 1H), 7.58 (d, J= 8.4 Hz, 2H), 7.50 (dd, J= 8.0, 2.0 Hz, 1H), 7.30 (d, J=
8.4 Hz, 1H), G.8G (t, J= 5.2 Hz, 1H), 4.18 (s, 2H), 4.04 (s, 2H), 2.81 (s, 3H), 2.73 (s, 3H), 2.28 (s, 3H). MS (ESI) m/e: 490 (M++1).

H
O O Nw ~N
N~N I \ N \ I ~Nw ,N ~ O O
I
The title compound was synthesized following the procedure for the preparation of Example 1 utilizing Example J and Reagent AA to yield N1,N~-bis((methylcarbamoyl)methyl)-N4-(3-(4-phenylpyrimidin-2-ylamino)-4-methylphenyl)terephthalamide.'H NMR (DMSO-d~) 8 10.25 (br s, 1H), 8.85 (br s"
1H), 8.44 (d, J = 4. 8 Hz, 1 H), 8.40 (d, J = 3.2 Hz, 1 H), 8.19 (m, 1 H), 8.11 (d, J =
5.8 Hz, 1 H), 8.06 (s, 1 H), 7.97 (d, J = 8.4 Hz, 2H), 7.50-7.45 (m, 5H), 7.32 (d, J = 5.2 Hz, 1 H), 7.18 (d, J = 8.0 Hz, 1H), 4.00 (s, 2H), 3.87 (s, 2H), 2.63 (d, J= 4.0 Hz, 1H), 2.58 (d, J= 4.0 Hz, 1H), 2.21 (s, 3H); MS (ESI) m/e: 566 (M++1).
EXAMPLE K
~ ~ON
s O
To the solution of Reagent AA (840 mg, 2.72 mmol) and 4-hydroxymethyl-benzoic acid (490 mg, 3.20 mmol) in dry DMF (20 mL) was added EDCI (700 mg, 3.62 mmol), HOBt (500 mg, 3.73 mmol), and NMM (0.5 mL, 3.95 mmol): The resulting mixture was stirred at RT overnight, into HZO and extracted with CHZC12. The organic layer was washed with saturated NaZC03, purified by column chromatography on silica gel yielded N-(3-(4-phenylpyrimidin-2-ylamino)-4-methylphenyl)-4-(hydroxymethyl)benzamide (410 mg, 36.8%). 'H NMR (DMSO-d~) 8:10.12 (s, 1H), 8.84 (s,lH), 8.44(d, J= 5.2 Hz, 1H), 8.11(d, J
= 4.0Hz, 2H), 8.05 (s, 1H), 7.91(d, J = 8.OHz, 2H) 7.45(m,SH), 7.32(d, J = 5.2 Hz, 1H), 7.19(d, J= 7.8 Hz, 1H), 4.56(d, J= 5.6 Hz, 2H), 2.30(s, 3H); MS(ESI) n~/e:
411.20(M++1).
EXAMPLE L
ci N\ /N ~ NIf~I //
rN~ ~ / O
To the solution of Example K (410 mg, 0.99 mrnol) in 1,4-dioxane (40 mL) was slowly added SOC12 (650 mg, 5.50 mmol) at RT. After being stirred at RT for 3h, the solvent and excessive SOC12 was removed in vacuo to yield N-(3-(4-phenylpyrimidin-2-ylamino)-4-methylphenyl)-4-(chloromethyl)benzamide as a yellow solid (460 mg), which was used without further purification. 1H NMR (CDCl3-d~) 8:8.42(s, 1H), 8.22(d, J =
6.OHz, 3H), 8.05(m, 1H), 7.94(d, J= 1.0 Hz, 2H) 7.53-7.62(m,SH), 7.26(s,2H), 4.63(d, J=
5.4 Hz, 2H), 2.44(s, 3H); MS(ESI) m/e: 429.20(M++1) EXAMPLE M
o~NH
\ N~S~O
To the solution of phenyl-urea (l3.Og, 95.48 mol) in THF (100 mL) was slowly added chlorocarbonyl sulfenylchloride (13 mL, 148.85 nnnol) at RT. The reaction mixture was refluxed overnight, the volatiles removed in vacuo yielded 2-phenyl-1,2,4-thiadiazolidine-3,5-dione as a white solid (4.Og, yield 20%). IH NMR (DMSO-d~) ~: 12.49 (s, 1H), 7.~ 1 (d, J= 8.0 Hz, 2H), 7.43(t, J= 7.6 Hz, 2H), 7.27 (t, J= 7.2 Hz, 1 H).

I N~N ~ I
I N~b I \ b~ s-O
,N ~ O
~I
To a solution of Example M (400 mg, 2.06 mmol) in anhydrous DMF and THF (l:l) under NZ at 0 °C was slowly added NaH (165 mg, 4.24 mmol). After stirring at 0 °C for O.Sh, Example L (300 mg, 0.70 mmol) was added. The solution was heated to 40 °C, stirred for 3h and quenched with AcOH (0.5 mL). Removal of the solvent followed by purification via preparative HPLC yielded N-(3-(4-phenylpyrimidin-2-ylamino)-4-methylphenyl)-4-((3,5-dioxo-4-phenyl-1,2,4-thiadiazolidin-2-yl)methyl)benzamide (50 mg, yield 12 %).
~HNMR
(DMSO-d~) 8: 10.18(s, 1 H), 8.88(s, 1 H), 8.43(d, J= 5.2 Hz, 1H), 8.12(dd, J=
7.6 1.6 Hz, 2H), 8.05(s, 1 H), 7.92(d, J = 8.4 Hz, 2H), 7.58(d, J = 9.2 1.6 Hz, 2H), 7.44-7.50(m, 8 H), 7.34(t, J= 6.0 Hz, 2H), 7.18(d, J= 8.8 Hz, 1H), 4.91(s, 2 H), 2.20(s, 3 H); MS
(ESI) (mle):
587.18(M~+1 ).
EXAMPLE N
MeOZC ~ ~ NH~COzEt Glycine ethyl ester hydrochloride (ll.lg, 79 mmol), and Reagent EE (lOg, G1 mmol) were dissolved in absolute EtOH (300 mL). NaCNBH3 (8.4g, 134nnnol) was added in 4 portions and the reaction mixture was stirred at RT overnight. The solvent was removed under reduced .pressure and the residue was dissolved in EtOAc. The organic layer was washed with 1N HCl solution, saturated NaHC03 and brine, and dried and concentrated .in vacuo to yield methyl 4-(((ethoxycarbonyl)methylamino)methyl)benzoate (8g). 'H-NMR
(CDC13): 7.97 (d, J= 6.8 Hz, 2H), 7.39 (d, J= 8.8 Hz, 2H), 4.16 (q, J= 7.2 Hz, 2H), 3.88 (s, 3H), 3.84 (s, 2H), 3.37 (s, 2H), 1.94 (s, 1H), 1.24 (t, J= 7.2 Hz, 3H).
EXAMPLE O
MeO2C
N
C ~S~~ OzEt HN
Cbz To a stirred solution of chlorosulfonyl isocyanate (2.2g, 15.2 mmol) in CHZCIz (40 mL) was added benzyl alcohol (1.64g, 15.2 mmol) at 0°C. And the reaction temperature was kept not to rise above 5°C. After stirred for lh, a solution of Example N (4.2g, 16.7 mmol) and triethylamine (6 mL, 4.3g, 42. 6 mmol) in CHZC12 (40 mL) was added at a rate to keep the reaction temperature not to rise above 5°C. When the addition was completed, the reaction solution was allowed to warm to RT and stirred overnight. The reaction mixture was poured into 1N HCl saturated with NaCI (300 mL). The organic layer was separated and the aqueous layer was extracted with CHZCIZ (2x100 mL). The combined organic layers were dried with Na2S04, and concentrated. The cmde product was recrystallized from CHZC12/n-hexane to afford desired Example O (5.9g, 76.6% yield). tH-NMR {CDCI3): 8.00 (d, J= 8. 4 Hz, 2H), 7.87 (s, 1H), 7.36 (m, SH), 5.29 (s, 2H), 4.65 (s, 2H), 4.15 (q, J=
7.2 Hz, 2H), 3.98 (s, 2H), 3.92 (s, 3H), 1.24 (t, 3H).
EXAMPLE P
MeOzC
N
~ SAO CO2Et HZN
To a solution of Example O (5.5 g, 118 mmol) in solvent of MeOH (50 mL) and EtOAc (50 mL ) was added 10% Pd/C (0.8 g ) under NZ. Then the resulting mixture was stirred at RT under HZ (60 psi) overnight. The solvent was removed to afford white solid Example P (3.4 g, 85% yield). 1H-NMR (CDC13): 8.02 (d, J= 8. 4 Hz, 2H), 7.41 (d, J= 8.4 Hz, 2H), 5.20 (s, 2H), 4.44 (s, 2H), 4.19 (q, J= 7.2 Hz, 2H), 3.91 (s, 3H), 3.90 (s, 2H), 1.25 (t, J= 7.2 Hz, 3H) EXAMPLE Q
MeO2C~ ~ ~ O
~N-SAO
~NH
O
A NaOMe solution was prepared by adding NaH (60%, dispersion in mineral oil, 43.5 S lllg, 1.1 mmol) to MeOH (30 mL). Example P (300 mg, 0.9 mmol) was added to the NaOMe-MeOH solution and the reaction was stirred at RT overnight. The solution was concentrated in vacuo and the residue was dissolved in H20 (30 mL). The aqueous solution was acidified with 3N HCl and the precipitate was altered and collected to yield methyl 4-(1,1,4-trioxo-[1,2,5]thiadiazolidin-2-yhnethyl)-benzoate (120 mg, 40% yield). 1H-NMR (DMSO-c~: 7.92 (d, .I= 8. 4 Hz, 2H), 7.49 (d, ,I= 8 Hz, 2H), 4.35 (s, 2H), 3.99 (s, 2H), 3.83 (s, 3H).
EXAMPLE R
Nooc ~ ~ o ~N-SAO
/NH
~O
Example Q (100 mg, 0.35 mmol) in THF (4 mL) and 1.5 mL of 2N aq. LiOH solution was stirred at RT for 3h. The solvent was removed under reduced pressure and the residue was dissolved in H20 (20 mL) and acidified with aqueous 3N HCl. The precipitate was filtered and collected to yield 4-(1,1,4-trioxo-[1,2,SJthiadiazolidin-2-ylmethyl)-benzoic acid (85 mg). 'H-NMR (DMSO-c~: 7.90 (d, .l= 8 Hz, 2H), 7.46 (d, J= 8.4Hz, 2H), 4.27-4.22 (br, 2H).

o~ .o s N N N ~ I N ,NH
iN I / O O
iN
The title compound was prepared following the procedure of Example 1 utilizing Example R and Reagent FF to yield N-[4-methyl-3-(4-phenyl-pyrimidin-2-ylamino)-phenylJ-4-(1,1,4-trioxo-[1,2,SJthiadiazolidin-2-ylmethyl)-benzamide (48% yield). 'H-NMR (DMSO) b 10.19 (s, 1 H), 9.3 0 (s, 1 H), 9.00 (d, 1 H), 8.72 (d, J = 5.2 Hz, 2H), 8.59 (d, J = 9.2 Hz, 1 H), 8.52 (d, J= 5.2 Hz, 2H), 8.08 (s, 1H), 7.92 (d, J= 8.4 Hz, 1H), 7.62 (m, 1H), 7.50-7.43 (m, 4H), 7.19(d, J = 8.4 Hz, 2H), 4.27(s, 2H), 3.86 (s, 2H), 2.20 (s, 3H). MS
(ESI) in/e:
530.1(M+1).

o~ .o s N N N ~ I ' i ,NH
iN I / O O
The title compound was prepared following the procedure of Example 1 utilizing Example R and Reagent AA to yield N-[4-methyl-3-(4-phenyl-pyrimidin-2-ylamino)-phenyl]
-4-(1,1,4- trioxo-[1,2,5]thiadiazolidin-2-ylmethyl)-benzamide (56% yield). 1H-NMR
(DMSO-c~:10.18 (s, 1H), 8 89 (s, 1H), 8.44 (d, J= 4.8 Hz 1H), 8.12 (d, J= 7.6 Hz, 2H), 8.05 (s, 1H), 7.92 (d, J= 8.0 Hz, 2H), 7.50-7.44 (m, 6H), 7.33 (d, J= 5.2 Hz, 1H);
7.18 (d, J= 8.4 Hz,.IH), 4.28 (s, 2H), 3.81 (s, 2H), 2.20 (s, 3H). MS (ESI) m/e: 529.1(M+1).
EXAMPLE S
N'S~N~COzEt Me0 I / Boc H
O
A solution of Reagent GG (lOg, 35.4m mol) and diisopropyl azodicarboxylate (7.2 g, 35.4 mmol) in THF (60 mL) was added dropwise (l5min, 5°C) to a solution of equal molar quantities of triphenylphosphine (9.3g, 35.4mmo1) and 4-hydroxymethyl-benzoic acid methyl ester (6g, 35.4m mol) in THF (50 mL). The resulting mixture was stirred under atmosphere for 2h. The solvent was removed and the residual was chromatographed to yield ethyl-[N-(N'-tent-butyloxycarbonyl,N~-benzoic methyl ester)-sulfamoyl]-glycinate as a white powder (8g, 53.3% yield). 1H-NMR (CDC13): 7.99 (d, J = 8.4 Hz, 2H), 7.42 (d, J
= 8.0 Hz, 2H), 5.80 (t, J 5.6 Hz, 1H), 4.85 (s, 2H), 4,12 (q, J= 7.2 Hz, 2H), 3.90(s, 3Ii), 3.65 (d, J =
5.6 Hz, 2H), 1.49 (s, 9H), 1.24 (t, 3H).

EXAMPLE T

N ~ ~N ~COZEt Me0 ~ / H H
O
The solution of Example S (3g, 7m mol) in 2N HCl/dioxane 1,4-dioxane (60 mL) was heated to 50°C for 15 min. Then the solvent was removed under reduced pressure to yield ethyl-[N-(N'-benzonic methyl ester)-sulfamoyl]-glycinate as a white solid (2g, 86.9% yield).
IH-NMR (CDCl3): 8.01 (d, J = 8.4,2H), 7.41 (d, J = 8.4,2H), 4.86 (t, J = 4.8 Hz, 1H), 4.70 (t, J = S.G Hz,IH), 4.32 (d, J = 6.4 Hz, 2H), 4.21 ~(q, J = 7.2 Hz ,2H), 3.91(s,3H), 3.82 {d, J = S.&
Hz, 2H), 1.28 (t, 3H).
EXAMPLE U
~s o N 'NH
M e0 I ~-//
O
O
A solution of Example T (lg, 30.3 mmol) and NaH (0.32g, 78.7m mol) in THF (120 mL) was heated to reflex for 8h. The mixW re was cooled to RT, then quenched with 1N aq.
HCl (100 mL) and extracted with CHZC12 (3 x 100 mL). The combined organic layers were f5 dried (Na2S04), and concentrated in vacuo and purified by flash chromatography to yield 4-(1,1,3-trioxo-[1,2,5]thiadiazolidin-2-ylmethyl)-benzoic acid methyl ester as a white powder (200mg, 23% yield). 1H-NMR (CDC13) 8.02 (d, J = 8.4, 2H), 7.48 (d, J = 8.0 Hz, 2H), 5.02 (br s, 1H), 4.77 (s, 2H), 4.10 (d, J = 7.2 Hz, 2H), 3.90 (s, 3H) EXAMPLE V
o.o N S.
' 'NH
HO I ~i O
O
Example LT (2OOmg, 0.8m mol) in THF (3 mL) and 2N aq. LiOH (1.5 mL) was stirred at RT for 3h. The solvent was removed under reduced pressure, and the aqueous layer was acidified with 3N aq. HCl solution to yield 4-(1,1,3-trioxo6-[1,2,5]thiadiazolidin-2-yhnethyl)-benzoic acid a white powder (120 mg, 63%). 1H-NMR (DMSO-d): 7.90 (d, J = 8.4 Hz, 2H), 7.43 (m, 2H), 4.10 (d, J =.6.0 Hz, 2H), 3.SG (d, J= 6.0 Hz, 2H).

NY ~ a ~ / N ,NH
I
I ~N ~ 0 N
The title compound was prepared following the procedure of Example 1 utilizing Example V and Reagent FF to yield N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]-4-(1,1, 3-trioxo-[1,2,5]thiadiazolidin-2-ylmethyl)-benzamide (65%
yield). 1H-NMR
(DMSO-d): 10.19 (s, 1H), 9.27 (s, 1H), 8.97 (s, 1H), 8.69 (d, J = 4.8 Hz, 2H), 8.60 (d, J = 6.4 Hz , 2H), 8.52 (m, 1H), 8.06 (s, 1H),7.89 (d, J = 7.6 Hz, 5H), 7.55 (d, 1H), 7.47-7.41 (m, 4H), 7.18 (d, J = 7.4 Hz, 2H), 4.76 (s, 2H), 4.15 (d, J = 6.4 Hz, 2H), 2.20 (s, 3H); MS (ESI) m/e: 530.1 (M+1).
i0 H ~N H
N Y N '~ b ~'~'i ~N I i O
i The title compound was prepared following the procedure of Example 1 utilizing Example V and Reagent AA to yield N-[4-Methyl-3-(4-phenyl-pyrimidin-2-ylamino)-phenyl]-4-(1,1,3-trioxo-[1,2,5]thiadiazolidin-2-ylmethyl)-benzamide (67%
yield). 1H-NMR
DMSO): 10.18 (s,lH), 8.85 (s, 1H), 8.61(m, 1H), 8.43 (d, J= 5.2 Hz, 2H), 8.10 (d, J= 6.2 Hz, 2H), 8.04 (s, 1 H), 7.90 (d, J = 8.0 Hz , 2H), 7.4 (m, SH), 7.32 (d, J =
5.2 Hz, 1 H) ,7.18 (d, J= 8Hz, 1H), 7.05 (s, 1H), 6.93 (s, 1H), 4.76 (s, 2H), 4.16 (d, J= 6.4 Hz, 2H); Ms (ESI) mle: 529.1 (M+1) EXAMPLE W
~ '.o HOOC
TO a 501l1t1o11 Of 4-l7rOlllOlllethyl-henZlC aCld methyl ester (S.Og, 0.02 mol) and 4-thiomorpholine (2.02g, 0.02 mol) in acetonitrile (50mL) was added KZC03 (5.52g, 0.04 mol).
The mixture was stirred under reflex for two days. After filtration of inorganic salt and removal of solvent, the residue was added to conc. HCI. The mixture was stirred at RT for 30 min, concentrated, dissolved in acetic acid (30 mL) and 30% hydrogen peroxide (10 mL), stirred at 100 °C for overnight and then cooled to 0°C. Zinc powder (1:5 g)' was added to the reaction solution. After being stirred for 30 min, the resulting mixture was filtered and solid was washed with MeOH. The filtrate was concentrated. The residue was neutralized by 2N
solution of KZC03 and adjust to PH= 8-9. The solution was extracted with CHZCl2 twice.
The combined organic layers were dried over Mg2S04, and concentrated. The residue was added conc. HCl (lOmL). The resulted solution was stirred at 80 °C
fom2h and concentrated to yield 4-(4,4-dioxothiomorpholinomethyl)benzoic acid (1.02 g, 18%). 1H NMR
(D20) 87.98 (d, J = 8.0 Hz, 2H), 7.52 (d, J = 8.0 Hz, 2H), 4.45 (s, 2H), 3.79 (s, 4H), 3.53 (s, 4H);
MS (ESI) n~/e: 270 (M++1).

/ N
N~ N \ N \ I \°O
O
iN ~ / O
To a solution of Reagent BB (100 mg, 0.5 mmol) in the anhydrous DMF (3 mL) at RT
was added Example W (200 mg, 0.77 11111101) followed by EDCI (200 mg,.1.20 nunol), HOBt (200 lllg, 1.15 mmol) and NMM (0.5 mL). After being stirred at RT overnight., the mixture was added to H20 (100 mL) and extracted with CHZC12 (2x100 mL). The combined organic layers were washed with brine, dried (NaZS04) and concentrated. The residue was purified by preparative HPLC to yield 4-(((4,4-dioxothiomorpholinomethyl)1)methyl)-N-(4-methyl-3-(pyrimidin-2-ylamino)phenyl)benzamide (100 mg, 44%). 1H NMR (DMSO-d6): 8.43 (d, J=
4.8 Hz, 2H), 8.29 (s, 1H), 7.86 (d, J= 8.4 Hz, 2H), 7.81 (s, 1H), 7.46 (d,'J=
7.6 Hz, 3H), 7.21 (d, J= 8.4 Hz, 2H), G.75 (t, J= 4.8 Hz, 1H), 3.72 (s, 2H), 3.10 (s, 4H), 3.03 (s, 4H), 2.32 (s, 3H); MS (ESI) n~/e: 452 (M++1).

H hl / I N
N'\ / N \ N =O
\ ~SO
~ ~N ~ / o The title compound was prepared following the procedure of Example 13 utilizing Example W and Example AA to yield 4-(((4,4-dioxothiomorpholinomethyl)1)methyl)-N-(4-methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl)benzamide. 'H NMR (CDC13): 8.54-8.52 (m, 2H), 8.49-8.11 (m, 2H), 7..88-7.83 (m, 2H), 7.80 (s, 1H), 7.50-7.39 (m, 6H), 7.23-7.15 (m, 2H), 7.02 (s, 1H), 3.73 (s, 2H), 3.12 (s, 4H), 3.01 (s, 4H), 2.38 (s, 3H);
MS (ESI) mle:
528 (M++1).

NI
Nw N \ N \ I ~SvO
O
iN I / O
Co~
The title compound was prepared following the procedure of Example 13 utilizing Example W and Example HH to yield 4-(((4,4-dioxothiomorpholinomethyl)1)methyl)-N-(4-methyl-3-(4-morpholinopyrimidin-2-ylamino)phenyl)benzamide. 'H NMR {CDC13):
8.63 (s, 1 H), 8.00 (d, J = 6.0 Hz, 1 H), 7. 82 (d, J = 8.0 Hz, 2H), 7.77 (s, 1 H), 7.43 (d, J = 8.4 Hz, 2H), 7.1G-7.09 (111, 2H), G.72 (s, 1H), G.02 (d, J= G.4 Hz, 1H), 3.80-3.77 (m, 4H), 3.GG (s, 2H), 3.58 (s, 4H), 3.07 (s, 4H), 3.00-2.88 ( n~, 4H), 2.30 (s, 3H); MS (ESI) n~l/e:
537 (M++1).
EXAMPLE X

\ N ~O
HO I / _ O
To a solution of D-4-phenyl-oxazolidin-2-one (lg, G nnnol) in anhydrous THF
(40 mL) under nitrogen protection at -78°C was added BuLi (2:5 M in hexane, 1.8 mL, 4.5 mmol). After one hour, the mixture was transferred to a solution of terephthalic acid chloride monobenzyl ester (prepared from Reagent DD (1.2 g, 4.5 11111101) and thionyl chloride (10 mL) at. reflux for 2h), in anhydrous THF. After being stirred at -78 °C
for 30 111111, the reaction mixture was warmed to RT for 2h. After Being quenched by adding sat<lrate solution of ammonium chloride (1 mL), the reaction solution was extracted with CHaCl2 (3 x SO mL).
The combined organic layers were dried (Na2S04) and concentrated. The residue was dissolved in MeOH (20 mL) and 5% Pd/C (0.1 g) and stirred under 1 atln HZ for 5h. The suspension was filtered and filtrate was concentrated to yield D-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-benzoic acid (O.GS g, 4G%). 'H NMR (CDCl3): 8.15-8.11 (m, 2H), 7.70 (dd, .l = 6.8, 1.G Hz, 2H), 7.44-7.33 (m, 5H), 5.63 (dd, J= 8.8, G.8 Hz, 1H), 4.78 (dd, J--18, 9.2 Hz, 1H), 4.36 (dd, J= 9.2, 6.8 Hz, 1H); MS (ESI).m/e: 312 (M++1).
EXAMPLE Y

\ N~o Ho o \
The title compound was prepared following the procedure of Example X utilizing L-4-phenyl-oxazolidin-2-one to yield L-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-benzoic acid (0.65 g, 46%). ~H NMR (CDC13): 8.15-8.11 (m, 2H), 7.70 (dd, J = 6.8, 1.6 Hz, 2H), 7.44-7.33 (m, SH); 5.63 (dd, J= 8.8, 6.8 Hz, 1H), 4.78 (dd, J-- 18, 9.2 Hz, 1H), 4.36 (dd, J=
9.2; 6.8 Hz, 1H); MS (ESI) m/e: 312 (M++1).

N~o N_\ /N \ N \
TN ~ C \
The title compound was prepared following the procedure of Example 13 utilizing Example X and Reagent AA to yield D-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-N-(4-methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl)benzamide. 'H NMR (DMSO-d6) :
10.34 (s, 1 H), 8.87 (s, 1 H), 8.44 (d, J = 5.2 Hz, 1 H), 8.12-8.10 (m, 2H), 7.96 ( d, J = 8.4 Hz, 2H);
7.84 (d, J= 8.4 Hz, 2H), 7.54-7.30 (m, 8H), 7.19 (d, J= 8.4 Hz, 1H), 5.63 (dd, J 8.0 & 8.0, 1H), 4.84 (t, J 8.0, 1H), 4.23 (dd, .I--8.0 & 8.0, 1H), 2.21 (s. 3H). MS (ESI) m/e: 570 (M++1) N ~O
N\ N \ N \
I i o 1 ~
I
\
The title compound was prepared following the procedure of Example 13 utilizing Example Y and Reagent AA to yield L-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-N-(4-methyl-3-(4-phenylpyrimidin-2-ylamino)phenyl)benzamide. 'H NMR (DMSO-d6) :
10.34 (s, 1H), 8.87 (s, 1H)a 8.44 (d, J= 5.2 Hz, 1H), 8.12-8.10 (m, 2H),,7.96 ( d, J= 8.4 Hz, 2H), 7.84 (d, J= 8.4 Hz, 2H), 7.54-7.30 (m, 8H), 7.19 (d, J= 8.4 Hz, 1H), 5.63 (dd, J--8.0 & 8.0, 1H), 4.84 (t, J°8.0, 1H), 4.23 (dd, J--8.0 & 8.0, 1H), 2.21 (s. 3H). MS
(ESI) m/e: 570 (M++1) / N ~O
N\/N \ N \ I\
I iN ( / C
\ N
The title compound was prepared following the procedure of Example 13 utilizing Example X and Reagent FF to yield D-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]benzamide.lH NMR (DMSO-d6):
10.34 (s, 1H), 8.95 (s, 1H), 8.66 (m, 1H), 8.48 (m, 2H), 8.07 (s, 1H), 7.96 ( d, J= 8.4 Hz, 2H), 7.84 ( d, J = 8.0 Hz, 2H), 7.58-7.42 (m, 4H), 7.41-7.36 (m, 3H), 7.32 (d, J = 6.8 Hz, 1H), 7.20 (d, J= 8.4 Hz, 1H), S.G3 (t, J= 7.G Hz, 1H), 4.84 (t, J= 7.6 Hz, 1H), 4.23 (t, J=
7.6 Hz, 1H), 2.21 (s, 3H. ); MS (ESI) n~/e: 571 (M++1).

N ~O
N\ N \ N \
/ o. ~
/ I
\ N
The title compound was prepared following the procedure of Example 13 utilizing Example Y and Reagent FF to yield L-4-(2-oxo-4-phenyl-oxazolidine-3-carbonyl)-N-[4-methyl-3-(4-pyridin-3-yl-pyrimidin-2-ylamino)-phenyl]benzamide.~H NMR (DMSO-~l6):
10.34 (s, 1 H), 8.95 (s, 1 H), 8.66 (111, 1 H),. 8.48 (m, 2H), 8.07 (s, 1 H), 7.96 ( d, J = 8.4 Hz, 2H), 7.84 ( d, J = 8.0 Hz, 2H), 7.58-7.42 (m, 4H), 7.41-7.36 (m, 3H), 7.32 (d, J = 6.8 Hz, 1 H), 7.20 (d, J = 8.4 Hz, 1 H), 5.63 (t, J = 7.6 Hz, 1 H), 4.84 (t, J = 7.6 Hz, 1 H), 4.23 (t, J =
7.6 Hz, 1H), 2.21 (s, 3H. ); MS (ESI) n~/e: 571 (M++1).

EXAMPLE Z

\ N N
/O ~ / O~NH
O
To a solution of 1-methyl-[1,2,4]triazolidine-3,5-dione (1.886g, O.O1G4 mol) and sodium hyhride (200 mg) in DMSO (5 mL) was added 4-chloromethyl-benzoic acid methyl ester (1.0 g, 0.0054 11101). The mixture was stirred at RT for overnight, quenched with HZO
(100 mL), and extracted by CHZC12. The organic layer was washed with H20, dried (Na2S04) and concentrated in vacuo to yield methyl 4-((1-methyl-3,5-dioxo-1,2,4-triazolidin-4-yl)methyl)benzoate (1.02g, 72%). 'H NMR (CDC13) :7.93 (d, J= 8.4 Hz, 2H), 7.27 (d, J=
8.4 Hz, 2H), 4.68 (s, 2H), 3.83 (s, 3H), 3.27 (s, 3H). MS (ESI) m/e: 264 (M++1) EXAMPLE AA

\ N N.
HO I / ~-NH
O
O
A solution of Example Z (1.Og, 0.0038 mol) and lithium hydroxide (0.950g) in MeOH
(10 111L) was stirred at RT for overnight. The mixWre was acidified by 2N HCI
to pH=5-6 and extracted by CHZC12 (3x50 mL). The combined organic layers were washed with HZO, dried (MgS04) and concentrated in vacuo to yield 4-((1-methyl-3,5-dioxo-1,2,4-triazolidin-4-yl)methyl)benzoic acid (O.G g, 64%). IH NMR (CDCl3): 7.71 (d, J= 8.4 Hz, 2H), 7.17 (d, J=
8.4 Hz, 2H), 4.68 (s, 2H), 2.90 (s, 3H), 2.6 (s, 3H); MS (ESI) m/e: 249 (M++1).

/ N~NH
N\ N \ N \ I O~-N
rN I / O

\ N
The title temperature was prepared following the procedure of Example 1 utilizing Example AA and Reagent FF to yield N-(3-(4-(pyridin-3-yl)pyrimidin-2-ylamino)-methylphenyl)-4-((1-methyl-3,5-dioxo-1,2,4-triazolidin-4-yl)methyl)benzamide.
'H NMR
(CD30D) 89.44 (s, 1 H), 8.79 (d, J = 8.0 Hz, 2H), 8.50 (d, J = 4.0 Hz, 1 H), 8.25 (s, 1 H), 7.93 (d, J = 8.0 Hz, 2H), 7.73 (s, 1 H), 7.4G (d, J =8.0 Hz, 2H), 7.40 (d, J = 5.2 Hz, 1 H), 7.35 (d, J

= 8.4 Hz, 1H), 7.25 (d, J= 8.4 Hz, 1H), 4.87 (s, 2H), 3..07 (s, 3H), 2.31 (s, 3H): MS (ESI) m/e: 509(M++1).

/ N~NH
N~ N \ N \ ~ . ~N
O
iN ~ / O
The title temperahue was prepared following the procedure of Example 1 utilizing Example AA and Reagent AA to yield N-(3-(4-phenylpyrimidin-2-ylamino)-4-methylphenyl)-4-((1-methyl-3,5-dioxo-1,2,4-triazolidin-4-yl)methyl)benzamide.

(CD30D) : 8.39 (s, 1H), 8.20 (d, J= 1.6 Hz, 1H), 8.13 (m, 2H), 7.93 (d, J= 8.4 Hz, 2H), 7.47 (m, 6H), 7.27 (m, 2H), 4.59 (s, 2H), 3.08 (s, 3H), 2.31 (s, 3H). MS (ESI) m/e:
508 (M++1).

N~NH
N~ N \ N \ ~ O~-N
o \
The title temperature was prepared following the procedure of Example 1 utilizing Example AA and Reagent BB to yield 4-((1-methyl-3,5-dioxo-1,2,4-triazolidin-4-yl)methyl)-N-(4-methyl-3-(pyrimidin-2-ylamino)phenyl)benzamide. 1H NMR (CDC13) : 11.31 (s, 1H), 10.15 (s, 1H), 8.77 (s, 1H), 8.33 (m, 2H), 7.87 (m, 3H), 7.40 (m, 3H), 7.14 (d, J = 8.4 Hz, 1H), 6.71 (m, 1H), 4.73 (s, 2H), 2.97 (s, 3H), 2.14 (s, 3H); MS (ESI) m/e: 432 (M++1).
EXAMPLE BB
N~CO~Et O=S=O
MeO~C NHCbz To a stirred solution of chlorosulfonyl isocyanate (2.2 g, 15.2 11111101) in CHZC12 (40 niL) was added benzyl alcohol (1.64 g, 15.2 mmol) at 0°C. After being stirred for 111, a solution of Example N (4.2 g, 16.7 mmol) and trlethyla111111e (6 111L, 4. 3 g, 42.6 11111101) in , CH2Cl2 (40 mL) was added at a rate so that the reaction temperature did not rise above S°C.

When the addition was completed, the reaction solution was allowed to warm to RT and stirred overnight. The reaction mixture was then poured into 1 N HCl saturated with NaCI
(300 mL). The organic layer was separated and the aqueous layer extracted with CH2C12. The combined organic layers were dried over Na2S04, and concentrated to yield the cnide compound. Recrystallization from CHZC12/n-hexane yielded Example BB (5.9 g, 76.6%
yield). ~H-NMR (CDCl3) 8 8.00 (d, J= 8. 4 Hz, 2H), 7.87 (s, 1H), 7.36 (m, SH), 5.29 (s, 2H), 4.65 (s, 2H), 4.15 (q, J= 7.2 Hz, 2H), 3.98 (s, 2H), 3.92 (s, 3H), 1.24 (t, 3H).
EXAMPLE CC
MeO2C
O~~ N~
SAO C02Et To a solution of Example BB (5.5 g, 118 mmol) in MeOH (50 mL ) and EtOAc (50 mL ) was added 10% Pd/C (0.8 g ) under nitrogen atmosphere. Then the result mixture was stirred at ambient temperature under HZ (60 psi) overnight. The solvent was removed to yield Example CC (3.4 g, 85%) as a white solid. 'H-NMR (CDCl3, 8) 8.02 (d, J= 8. 4 Hz, 2H), 7.41 (d, J = 8.4 Hz, 2H), 5.20 (s, 2H), 4.44 (s, 2H), 4.19 (q, J = 7.2 Hz, 2I-I), 3.91 (s, 3H), 3.90 (s, 2H), 1. 25 (t, J= 7.2 Hz, 3H) EXAMPLE DD
Me0 C ~ ~ O
~N-S.O
/NH
~O
A NaOMe solution was first prepared by adding NaH (60%, dispersion in mineral oil, 43.5 mg, 1.1 mmol) to MeOH (30 mL). Example CC (300 mg, 0.9 mmol) was added to the NaOMe-MeOH solution and the reaction was stirred at RT overnight. The solution was concentrated to dryness in vacuum and the residue was dissolved in H20 (30 mL). The aqueous solution was acidified with 3 N HCl (aq. ) and the result precipitate was filtered and collected to yield Example DD (120 mg, 40% yield). tH-NMR ( DMSO-cl6) 7.92 (d, J= 8. 4 Hz, 2H), 7.49 (d, J= 8.4 Hz, 2H), 4.35 (s, 2H), 3.99 (s, 2H), 3.83 (s, 3H).

EXAMPLE EE
Hooc- ~~ ~-~ o ~N,s,o 'NH
~0 The solution of Example DD (100 mg, 0.35 11111101) in THF (4 mL) and 1.5 mL of aq. LiOH solution was stirred at RT for 3h. Then the solvent was removed under reduced pressure and the residue was dissolved in water (20 mL) and acidified with aqueous 3 N HCI.
The result precipitate was filtered to yield Example EE (85 mg). 1H-NMR ( DMSO-cl)8 7.90 (d, J= 8 Hz, 2H), 7.46 (d, J= 8.4Hz, 2H), 4.27-4.22 (br, 2H).

°. ,o N S
1 'NH
N~ N \ N
O O
,N
The title compound was prepared following the procedure of Example 1 utilizing Example EE and Reagent FF to yield Example 22. ~H-NMR (DMSO-cl~) 810.19 (s, 1H), 9.30 (s, 1 H), 9.00 (d, 1 H), 8.72 (d, J = 5.2 Hz, 2H), 8.59 (d, J = 9.2 Hz, 1 H), 8.52 (d, J = 5.2 Hz, 2H), 8.08 (s, 1H), 7.92 (d, J= 8.4 Hz, 1H), 7.62 (m, 1H)~ 7.50-7.43 (m, 4H), 7.19(d, J= 8.4 Hz, 2H), 4.27(s, 2H), 3.86 (s, 2H), 2.20 (s, 3H). MS (ESI) m/e: 530(M++1).

o~ ,o N S
/ 1 \NH
N\ N \ N \ ~\(\I
i ~ / O O
The title compound was prepared following the procedure of Example 1 utilizing Example EE and Reagent AA to yield Example 22. 'H NMR (DMSO-d~) 810.18 (s, IH), 8 89 (s, 1H), 8.44 (d, .I= 4.8 Hz 1H), 8.12 (d, J= 7.6 Hz, 2H), 8.05 (s, 1H), 7.92 (d, J= 8.0 Hz, 2H), 7.50-7.44 (111, 6H), 7.33 (d, J = 5.2 Hz, 1 H), 7.18 (d, J = 8.4 Hz, 1 H), 4.28 (s, 2H), 3.81 (s, 2H), 2.20 (s, 3H). MS (ESI) m/e:-529(M++1).

EXAMPLE FF
o,. ,,O
~ N~S~~~CO~Et MeO~Boc O
A solution of [Boc-sulfamide] amino ester (lOg, 35.4m m01) min) to a solution of triphenylphosphine (9.3g, 35.4nnnol) and 4-hydroxymethyl-benzoic acid methyl ester (6g, 35.4m mol) in THF (50 mL) at 0-5°C. The result mixture was stirred under NZ for 2h. The solvent was removed and the residual was purified by column chromatography to yield Example FF as a white powder (8g, 53.3% yield). 'H-NMR (CDCL3) 7.99 (d, J =
8.4 Hz, 2H), 7.42 (d, J= 8.0 Hz, 2H), 5.80 (t, J S.G Hz, 1H), 4.85 (s, 2H), 4,12 (q, J= 7.2 Hz, 2H), 3.90(s, 3H), 3.65 (d, J = 5.6 Hz, 2H), 1.49 (s, 9H), 1.24 (t, 3H).
EXAMPLE GG
o ,,o ~t~~COzEt Me0 I
O
The solution of Example FF (3g, 7m mol) in 2N HC1/dioxane 1,4-dioxane (60 mL) was heated to 50°C for 15 min. The solvent was removedin vacuo to yield Example GG as a white solid (2g, 86.9% yield). 'H-NMR ( CDC13,~) 8.01 (d, J = 8.4,2H), 7.41 (d, J = 8.4,2H), 4.86 (t, J = 4.8 Hz,lH), 4.70 (t, J = S.G Hz,lH), 4.32 (d, J = 6.4 Hz, 2H), 4.21 (q, J = 7.2 Hz ,2H), 3.91 (s,3H), 3.82 (d, J = 5.6 Hz, 2H), 1.28 (t, 3H).
EXAMPLE HH
Qs,o ~NH
Me0 I ,~-~/
O
A solution of Example GG (lg, 30.3 11111101) and NaH (0.32g, 78.7m mol) in THF
(120 mL) was heated t0 reflux for 8h. The mixture was cool to RT, quenched with 1N
aq. HCl solution (100 mL) and extracted with CHZC12 (3x100 mL). The combined organic phases were dried (NaZS04), and concentrated in vacuo and purred by flash chromatography to yield Example HH as a white powder (200mg, 23% yield). 'H-NMR (CDC13, ~) 8.02 (d, J =
8.4, 2H), 7.48 (d, J = 8.0 Hz, 2H), 5.02 (br s, 1H), 4.77 (s, 2H), 4.10 (d, J
= 7.2 Hz, 2H), 3.90 (s, 3 H) EXAMPLE II

~N H
HO
O
O
Example HH (200mg, 0.8m mol) was dissolved in THF (3 mL), and 1.5 rnL solution of 2N aq. LiOH was added to the reaction solution. The mixture was stirred at RT for 3h. The solvent was removed in vacuo, and the aqueous layer was acidified with 3N aq.
HCl solution, and filtered to yield Example II as a white powder (120mg, 63%). 'H-NMR (DMSO-d) 87.90 (d, J = 8.4 Hz, 2H), 7.43 (m, 2H), 4.10 (d, J = 6.0 Hz, 2H), 3.56 (d, J=
6.0 Hz, 2H).

N~S
~N H
I NYN I W N I ~ ~j-~
I O
iN ~ O y ~ N
The title compound was prepared following the procedure of Example 1 utilizing Example II and Reagent FF (65% yield). IH-NMR (DMSO-c~ 810.19 (s, 1H), 9.27 (s, 1H), 8.97 (s, 1 H), 8.69 (d, J = 4.8 Hz, 2H), 8.60 (d, J = 6.4 Hz , 2H), 8.52 (m, 1 H), 8.06 (s, 1 H),7.89 (d, J = 7.6 Hz, SH), 7.55 (d, 1 H), 7.47-7.41 (m, 4H), 7.18 (d, J =
7.4 Hz, 2H), 4.76 (s, 2H), 4.15 (d, J= 6.4 Hz, 2H), 2.20 (s, 3H); MS (ESI) mle: 530 (M+1).

N So ~NH
N~N ~ N
O
I ~N I / O
The title temperature was prepared following the procedure of Example 1 utilizing Example II and Reagent AA. (67% yield). ~H-NMR ( DMSO-~~, 510.18 (s,lH), 8.85 (s, 1 H), 8.61 (m, 1 H), 8.43 (d, J = 5.2 Hz, 2H), 8.10 (d, J = 6.2 Hz, 2H), 8.04 (s, 1 H), 7.90 (d, J
= 8.0 Hz , 2H), 7.4 (m, SH), 7.32 (d, J= 5.2 Hz, 1H) ,7.18 (d, J= BHz, 1H), 7.05 (s, 1H), 6.93 (s, 1 H), 4.76 (s, 2H), 4.16 (d, J= 6.4 Hz, 2H); Ms (ESI) m/e: 529 (M+1 ) Specific embodiments are additionally illustrated below which are intended to represent more clearly, but without limitation to the generic scope, the present invention:
Example 1 / wN,S
H H I ~0 Example 2 N~N \ N \ O~N
H.
/ 0 /. N,S
I-i H H I ~ ~O
N' /N \ N \ O H
\ II
O

i N
Example 3 / \N~S~
H H I 0 .
N~ N ~ \ N 0 N
O H Example 4 / ~3C /
N H H H
N I N \ N II N
0 ~, O
/ ~3~.r ~ /
N
C~

Example 5 O ~p H H W I N~S~ Example G
N' /N . N \ ~NH
w~ \ HsC

I ~ ~3C I ~ / O O / . N O
H H ~ I I \N H
\ I N I N I \ N \ s 1 H3C o N ~ ~3C / O
y N
Example 7 / ~S~
H H I ,N~
I \~N H
\ H C
I N\ N \ N H3C Example 8 N H H H
N _N I \ N_ /N
O , I~3C / 'IO
N
C~~

Example 9 O
~N
N N . N \ I N OH Example 10 \ a O
I ~~ C I ~ O O

H H I 'N OH
\N I N~N I \ N O \ iN vOH

/ / 1'13C
O
/
N
Example 11 O
~N
H H OH
N\ N \ N \ ( ~N OH
HsC 0 O Example 12 .
N
H H H
O N N N N
\
I / ~3~ I ~ o N N OH

HsCm O

Example 13 H O
H H / H N ~O N
N' /N ~ ~ N ~ H3C O CH3 Example 14 ~ I~sC / O sC N O
H H / H N ~O
N~N ~ \ N ~ H3C O CH

N
Example 15 / H O
H H \ I \HN o O N
N\' /N ~ ~ N
H3C -~ ~CH3 N~ O
/ 3C Example 16 N
H H
O ~ \' /N ~ ~ N' ~~sC / CC
N
coy lOG

Example 17 /.I ~N'1 N\ N ~ N ~ ~SO O Example 18 N~ / O /
H Fi I
~O
S~
O
Example 19 / N
~S=
INN I ~ N ~ 'O
Example 20 O
/ ~30 /
N N\ N \ N~ \
H N
C~ I ~ I O ~
o / ~3~ /
N C NJ
~O~ ~S ~
O ~O

Example 2l. O NH Example 22 O\ ~NH
y / S~OEt / I S~OEt H H H H
N N \ N \ I N~N \ N \
N I O

\ I \
/N NJ
Example 23 NH Example 24 O~ //
/ S~OEt H H H
H H Nw N \ N II N \
N~ N \ N \ ~ I I O I O
/ / / //
I / ~3C ~ / O H3C I ~NH
N \ OEt N
C~
O
l08 Example 25 °
/I
H H
I N~N I \ N \ N
/ ~ C / O O~0 \ Example 2G °
I ~ /
/ N H H I ~N
IsI~NIw N \
/ ° ° o I
N
Example 27 O
/I
H H N
I N~NN I \ N \
/ HsC / O O O
Example 28 N
H H H
O Nw N \ N II N
I /1' I / O

N
C°

Example 29 / ~N
H H
N N N \ I
I ~ I ~ 1 /N / O 'S03H
Example 30 / .
/N Nw N \ N \ I N
O
I / ~3C I / S03H
Example 31 N
I N~N I \ N
H H \ I \ ~N1 N~ O I
/ HsC / \SO3H
Example 32 N
C~
O H H H
N ' N I \ N " N I \
O /
N NJ
C ~ CN
O

Example 33 / \N~S~
W I O
N' /N \ N \ ~
\fY O"N
/ p H

Example 34 / . I \N/S~
~H H O
N' /N \ N \ ~
Oi \N
O Fi I~~,C I/

Example 35 ,S
H / I ~ ~O
N~N I \ N \ O N

~~ C / O

Example 36 H H
N N N N
\
I ~N I ~ p N ~S
O
N O

Example 37 O
'~ ~O
/ I NHS
H H \N H
N~N \ N \ H3C
O H3C'~~/O
/
Example 38 O
I 'N
H H / ~S\
NH
N\I N I \ N \ HsC . \\

/

Example 39 O O
v ~i / \N~S
H H I \N H
I \~N I \ N \ H3C
O HsC O Example 40 ~~ C /

H H H
N\1 N I \ N II N
O /
NH C /

H C N ~S~O

O

Example 41 O
OH
H H I _N~
I N_ 'N I \ N \ N OH

~~C / O

Example 42 O
/ ~N
H H OH
N\ N \ N \ I ~N OH
HsC O
~~ C I / O

Example 43 O
/ ~N\~OH
H H I N OH
N~N I \ N \ H3C~ O
O

Example 44 H. H H
N N N N
\
I ~~ C I / O

N O
HaC N
O
O OH

Example 45 H O
O' H H / ~ ~HN o N
/ O sC J
\~N ~ \ N \ HsC CHs Example 46 H O
H H / ~ HN~O N
J
N~N I \ N \ HsCO CHs NH C / O sC

Example 47 H O
H H / ~ wHNO N
O' yN ~ \ N \ HsC CHs ~~ C / O sC

Example 48 H H H
N~N ~ \ N~N
C / IOI /
O H

N O~NH
HsC O CHs CHs Example 49 N
H H I ~g~0 ( N\ /N I ~ N ~ p O
C / O

Example 50 / ~N~
H H I ~~ c0 N' /N ~ N ~ " SO
I~\~~C I/ O

Example 51 / I N
H H 1' N~ N ~ N ~ VSOO
N O

Example 52 H H H
N N N N
I/
~~ C

N
O ~O

Example 53 O NH
~S
H H / I \OEt N~N I \ N \
~~ C / O

Example 54 NH
~S/
/ I ~OEt H H
I N~N I \ N \
/ O

Example SS
NH
O
H H / I ~OEt N~N I \ N \
O

Example 56 H H H
N~N .I \ N II N I \
O / O
\S=NH
I
OEt Example 57 O
/\
H H N
N~N L \ N \ O
O
C / Exam le 58 s p O
/ ~ ~ / \
H H N
N' /N ~ ~ N ~
O
~~ C / O O

Example 59 O
/\
H H. N
\~N I \ N
~~ C / O O

Example 60 H H H
N N N N
~~ C ~ /

O
O~N

Example 61 ~N
H H
N N N
\ 1 i~, ~ ~ O 'SO H Example 62 N
H H L
Nw N , \ N \ ~ ~N
N~ O ~SO3H

Example 63 H H \ I \N~
N~N \ N
~ ~ C ~ ~ O ~S03H

Example 64 H H H
N N N N \
\
~~ C ~ ~ O

N
N

Example 65 / I \N~S~
O.
\ N \
O~N
/ O I-I
CI
Example 66 / N ''S
I ~ ~O
N~N \ O NH
~'=-~~S O
Example 67 / I N~S
H O
/N \ N \ O~N

I O H
Example 68 N N
O
~N ~ / O ~ /
N U
Et N
O~ ~S
N
ti ~O

Example 69 O O
a ~~
~S
H /, . I \ N \N H
\ N \ H3C
'. HaC. O
O
CI Example 70 H ~ N~S~NH
N N \ I HsC ' '\

O
Example 71 ~,O
N' I H I ~NH
/ N I \ N \ HsC--~~D/
HsC O
O

Example 72 H H H
N N
O~N I \ ~ I \
N
Et H3C N ~S

~~~,~.NH
O

Example 73 Example 74 O
O /
/ ~ HN OH H I Hi OH
H N N \ N OH
\ N \ ~N OH ~ ~ Ra O R4 O ~ S O O
CI /
Example 75 Example 76 O
H H
H / ~ HN OH N \ N~N \
/N \ N \ R4,N OH O~ I O
O N / /
H3C ~ / O Et N
Ra,N~O
O HO OH

Example 77 / NON
H I HO
\ N \ H3C -i ~CH3 O sC
CI /
Example 78 H O
H / HN~ON
N N \ I HsCO CHs sC

Example 79 H O
H / HN~ON
/ ~ \ N \ I HsCO CHs HsC / Example 80 H H H
N I \ N II N I \
O
N / O /
Et~ O HO
'~ N
HsC OCHs Example 81 \N~
H ~ ~ ,O
\ N \ " SO
O
Example 82 ~N~
H
N' N \ I ~SO p O
Example 83 ~N~
H
\ N \ ~ ~SO
O
HsC
Example 84 H H H
N ~ \ N~N ~ \
IIO
~N ~ O
CND
o S°O

Example 85 \\ ~NH
S
H / ~ \OEt \ N \
/ O
CI
Example 86 \ ~NH
S
H / . ~ ~OEt N~N
O
Example 87 NH
~S~
H / ~ ~OEt /I \ N \
/ . O

Example 88 H H H
N N N
\ ~ \
O~N ~ / O ~ / S/
Et ~ ~NH
Et0 Example 89 O
H N Ph N \
I~ °
Ci / ° °
Example 90 O
H Ph N N \ I N
°
Example 91 O
/ I
H N Ph \ N \
O
I/ °
HsC v Example 92 H H H
N I \ N II N I \
O
~N / ° /
Et~ ~O
O\ 'N .
--Ph ~/O

Example 93 / I N
H
\ N \ N \

CI
Example 94 / I N
H
O
N N \ N \
S03H' Example 95 I / I
H N
/N I \ N \

Example 9G
H H H
N N
O
~N I. / O I /
N U
Et CND
N

All of the references above identified are incorporated by reference herein.
In addition, two simultaneously applications are also incorporated by reference, namely Modulation of Protein Functionalities, S/N , fled December , 2003, and Anti-Inflammatory Medicaments, S/N filed December , 2003.

34479.sT25.txt SEQUENCE LISTING
<110> Deciphera Pharmaceuticals, Inc.
Flynn, Daniel L
Petillo, Peter A
<120> Anti-Cancer Medicaments <130> 34'479 <150> 60/437,403 <151> 2002-12-31 <160> 5 <170> Patentln version 3.2 <210> 1 <211> 292 <212> PRT
<213> Homo sapiens <400> 1 Gly Ala Met Asp Pro Ser Ser Pro Asn Tyr Asp Lys Trp Glu Met Glu Arg Thr Asp Ile Thr Met Lys His Lys Leu Gly Gly Gly Gln Tyr Gly Glu Val Tyr Glu Gly Val Trp Lys Lys Tyr Ser Leu Thr Val Ala Val Lys Thr Leu Lys Glu Asp Thr Met Glu Val Glu Glu Phe Leu Lys Glu 50 55 ~ 60 Ala Ala Val Met Lys Glu Ile Lys His Pro Asn Leu Val Gln Leu Leu Gly Val Cys Thr Arg Glu Pro Pro Phe Tyr Ile Ile Thr Glu Phe Met Thr Tyr Gly Asn Leu Leu Asp Tyr Leu Arg Glu Cys Asn Arg Gln Glu Val Asn Ala Va1 Va1 Leu Leu Tyr Met Ala Thr Gln Ile Ser Ser Ala Met Glu Tyr Leu Glu Lys Lys Asn Phe Ile His Arg Asp Leu Ala Ala Arg Asn Cys Leu Val Gly Glu Asn His Leu Val Lys Val Ala Asp Phe 34479.ST25.txt Gly Leu Ser Arg Leu Met Thr Gly Asp Thr Tyr Thr Ala His Ala Gly Ala Lys Phe Pro Ile Lys Trp Thr Ala Pro Glu Ser Leu Ala Tyr Asn Lys Phe Ser Ile Lys Ser Asp Val Trp Ala Phe Gly Val Leu Leu Trp Glu Ile Ala Thr Tyr Gly Met Ser Pro Tyr Pro Gly Ile Asp Leu Ser Gln Val Tyr Glu Leu Leu Glu Lys Asp Tyr Arg Met Glu Arg Pro Glu Gly Cys Pro Glu Lys Val Tyr Glu Leu Met Arg Ala Cys Trp Gln Trp Asn Pro Ser Asp Arg Pro Ser Phe Ala Glu Ile His Gln Ala Phe Glu Thr Met Phe Gln Glu Ser Ser Ile Ser Asp Glu Val Glu Lys Glu Leu 275 280 285' Gly Lys Arg Gly <210> 2 <211> 11 <212> PRT
<213> Homo Sapiens <400> 2 Val Glu Glu Phe Leu Lys Glu Ala Ala Val Met <210> 3 <211> 10 <212> PRT
<213> Homo Sapiens <220>
<221> MISC_FEATURE
<222> (1)..(11) <223> X is any amino acide <400> 3 His Arg Asp Leu Ala Ala Arg Asn xaa Leu 1 5 to Page Z

34479.ST25.txt <210> 4 <211> 9 <212> PRT
<213> Homo Sapiens <400> 4 Asp Phe Gly Leu Ser Arg Leu Met Thr <210> 5 <211> 7 <21~> PRT
<213> Homo sapiens <400> 5 Gly Asp Thr Tyr Thr Ala His

Claims (32)

We Claim:

1. A compound having the formula wherein:
R1 is selected from the group consisting of aryls and heteroaryls;
each X and Y is individually selected from the group consisting of -O-, -S-, -NR6-, -NR6SO2-, -NR6CO-, alkynyls, alkenyls, alkylenes, -O(CH2)h-, and -NR6(CH2)h-, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, -O(CH2)h-, and -NR6(CH2)h-, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that with -O(CH2)h-, the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of -C(O)-, -S(O)2-, -N(R6)CO-, -N(R6)SO2-, -N(R6)CON(R6)-;
j is 0 or 1;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;

Q is selected from tile group consisting of each R4 group is individually selected from the group consisting of -H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R5 is individually selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;
each R6 is individually selected from the group consisting of -H, alkyls, allyls, and .beta.-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of -H, -F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
G is selected from the group consisting of -O-, -S-, and -N(R4)-;
k is 0 or 1;
each Z is individually selected from the group consisting of -O- and -N(R4)-;
and each ring of formula (I) optionally includes one or more of R7, where R7 is a noninterfering substituent individually selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls;
except that:
when Q is Q-3 or Q-4, then the compound of formula (I) is not when Q is Q-7, then the compound of formula (I) is not when Q is Q-7, R5 is -OH, Y is -O-, -S-, or -CO-, m is 0, n is 0, p is 0, q is 0, and E is phenyl, then D is not thienyl, thiazolyl, or phenyl;
when Q is Q-7, then the compound of formula (I) is not when Q is Q-9, then the compound of formula (I) is not when Q is Q-10, then the compound of formula (I) is not wherein there is a bond between Q and of formula (I), and when Q is Q-11, t is 0, and E is phenyl, then any R7 on E is not an o-alkoxy in relation to said bond;
when Q is Q-11, then the compound of formula (I) is not when Q is Q-15, then the compound of formula (I) is not when Q is Q-16, then the compound of formula (I) is not when Q is Q-17, then the compound of formula (I) is not when Q is Q-21, then the compound of formula (I) is not when Q is Q-22, then the compound of formula (I) is selected from the group consisting of but excluding when Q is Q-23, then the compound of formula (I) is not when Q is Q-24, Q-25, Q-26, or Q-31, then is selected from the group consisting of wherein each W is individually selected from the group consisting of -CH- and -N-; and where * denotes the point of attachment to Q-24, Q-25, Q-26, or Q-31;
when Q is Q-31, then the compound of formula (I) is not when Q is Q-28, then the compound of formula (I) is not when Q is Q-32, then is not biphenyl, benzoxazolylphenyl, pyridylphenyl or bipyridyl;

when Q is Q-32, then the compound of formula (I) is not when Q is Q-35 as shown wherein G is selected from the group consisting of -O-, -S-, and -NR4-, k is 0 or 1, and u is 1, 2, 3, or 4, then is selected from the group consisting of except that the compound of formula (I) is not

2. The compound of claim 1, wherein R1 is selected from the group consisting of 6-5 fused heteroaryls, 6-5 fused heterocyclyls, 5-6 fused heteroaryls, and 5-6 fused heterocyclyls.

3. The compound of claim 2, where R1 is selected from the group consisting of each R2 is individually selected from the group consisting of -H, alkyls, aminos, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, halogens, alkoxys, and hydroxys; and each R3 is individually selected from the group consisting of -H, alkyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, alkoxys, hydroxys, cyanos, halogens, perfluoroalkyls, alkylsulfinyls, alkylsulfonyls, R4NHSO2-, and -NHSO2R4.

4. The compound of claim 1, wherein A is selected from the group consisting of phenyl, naphthyl, pyridyl, pyrimidyl, thienyl, furyl, pyrrolyl, thiazolyl, oxazolyl, imidazolyl, indolyl, indazolyl, benzimidazolyl, benzotriazolyl, isoquinolyl, quinolyl, benzothiazolyl, benzofuranyl, benzothienyl, pyrazolylpyrimidinyl, imidazopyrimidinyl, and purinyl.

5. A method of modulating the activation state of abl or bcr-abl .alpha.-kinase comprising the step of contacting said kinase with a molecule having the formula wherein:
R1 is selected from the group consisting of aryls and heteroaryls;
each X and Y is individually selected from the group consisting of -O-, -S-, -NR6-, -NR6SO2-, -NR6CO-, alkynyls, alkenyls, alkylenes, -O(CH2)h-, and -NR6(CH2)h-, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, -O(CH2)h-, and -NR6(CH2)h-, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that with -O(CH2)h-, the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of -C(O)-, -S(O)2-, -N(R6)CO-, -N(R6)SO2-, -N(R6)CON(R6)-;
j is 0 or 1;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;

Q is selected from the group consisting of each R4 group is individually selected from the group consisting of -H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R5 is individually. selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;
each R6 is individually selected from the group consisting of -H, alkyls, allyls, and .beta.-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of -H, -F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
G is selected from the group consisting of -O-, -S-, and -N(R4)-;
k is 0 or 1;
each Z is individually selected from the group consisting of -O- and -N(R4)-;
and each ring of formula (I) optionally includes one or more of R7, where R7 is a noninterfering substituent individually selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls;
and thereby causing modulation of said activation state.

6. The method of claim 5, said contacting step occurring at the region of a switch control pocket of said kinase.

7. The method of claim 6, said switch control pocket of said kinase comprising an amino acid residue sequence operable for binding to said Formula (II) molecule.

8. The method of claim 6, said switch control pocket selected from the group consisting of simple, composite and combined switch control pockets.

9. The method of claim 8, said region being selected from the group consisting of the .alpha.-C helix, the catalytic loop, the switch control ligand sequence, and the C-terminal lobe and combinations thereof.

10. The method of claim 9, said .alpha.-C helix including SEQ ID NO. 2.

11. The method of claim 9, said catalytic loop including SEQ ID NO. 3.

12. The method of claim 9, said switch control ligand sequence being selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, and combinations thereof..

13. The method of claim 9, said C-lobe residues including F.

14. The method of claim 5, said kinase selected from the group consisting of the consensus wild type sequence and disease polymorphs thereof.

15. The method of claim 5, said activation state being selected from the group consisting of the upregulated and downregulated states.

16. The method of claim 5, said molecule being an antagonist of the on switch control pocket for said kinase.

17. The method of claim 5, said molecule being an agonist of the off switch control pocket for said kinase.

18. The method of claim 5, said method including the step of administering said molecule to an individual undergoing treatment for cancer.

19. The method of claim 18, said molecule being administered by a method selected from the group consisting of oral, parenteral, inhalation, and subcutaneous.

20. The method of claim 5, said molecule having the structure of the compound of claim 1.

21. An adduct comprising a molecule binding with a kinase, said molecule having the formula wherein:
R1 is selected from the group consisting of aryls and heteroaryls;
each X and Y is individually selected from the group consisting of -O-, -S-, -NR6-, -NR6SO2-, -NR6CO-, alkynyls, alkenyls, alkylenes, -O(CH2)h-, and -NR6(CH2)h-, where each h is individually selected from the group consisting of 1, 2, 3, or 4, and where for each of alkylenes, -O(CH2)h-, and -NR6(CH2)h-, one of the methylene groups present therein may be optionally double-bonded to a side-chain oxo group except that with -O(CH2)h-, the introduction of the side-chain oxo group does not form an ester moiety;
A is selected from the group consisting of aromatic, monocycloheterocyclic, and bicycloheterocyclic rings;
D is phenyl or a five- or six-membered heterocyclic ring selected from the group consisting of pyrazolyl, pyrrolyl, imidazolyl, oxazolyl, thiazolyl, furyl, pyridyl, and pyrimidyl;
E is selected from the group consisting of phenyl, pyridinyl, and pyrimidinyl;
L is selected from the group consisting of -C(O)-, -S(O)2-, -N(R6)CO-, -N(R6)SO2-, -N(R6)CON(R6)-;
j is 0 or 1;
m is 0 or 1;
n is 0 or 1;
p is 0 or 1;
q is 0 or 1;
t is 0 or 1;

Q is selected from the group consisting of each R4 group is individually selected from the group consisting of -H, alkyls, aminoalkyls, alkoxyalkyls, aryls, aralkyls, heterocyclyls, and heterocyclylalkyls except when the R4 substituent places a heteroatom on an alpha-carbon directly attached to a ring nitrogen on Q;
when two R4 groups are bonded with the same atom, the two R4 groups optionally form an alicyclic or heterocyclic 4-7 membered ring;
each R5 is individually selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arylthios, cyanos, halogens, perfluoroalkyls, alkylcarbonyls, and nitros;
each R6 is individually selected from the group consisting of -H, alkyls, allyls, and .beta.-trimethylsilylethyl;
each R8 is individually selected from the group consisting of alkyls, aralkyls, heterocyclyls, and heterocyclylalkyls;
each R9 group is individually selected from the group consisting of -H, -F, and alkyls, wherein when two R9 groups are geminal alkyl groups, said geminal alkyl groups may be cyclized to form a 3-6 membered ring;
G is selected from the group consisting of -O-, -S-, and -N(R4)-;
k is 0 or 1;
each Z is individually selected from the group consisting of -O- and -N(R4)-;
and each ring of formula (I) optionally includes one or more of R7, where R7 is a noninterfering substituent individually selected from the group consisting of -H, alkyls, aryls, heterocyclyls, alkylaminos, arylaminos, cycloalkylaminos, heterocyclylaminos, hydroxys, alkoxys, aryloxys, alkylthios, arthylthios, cyanos, halogens, nitrilos, nitros, alkylsulfinyls, alkylsulfonyls, aminosulfonyls, and perfluoroalkyls.

22. The adduct of claim 21, said molecule binding at the region of a switch control pocket of said kinase.

23. The adduct of claim 22, said switch control pocket of said kinase comprising an amino acid residue sequence operable for binding to said Formula (III) molecule.

24. The adduct of claim 22, said switch control pocket selected from the group consisting of simple, composite and combined switch control pockets.

25. The adduct of claim 24, said region being selected from the group consisting of the .alpha.-C helix, the catalytic loop, the switch control ligand sequence, and the C-lobe, and combinations thereof.

26. The adduct of claim 25, said .alpha.-C helix including the sequence SEQ ID
NO. 2.

27. The adduct of claim 25, said catalytic loop including SEQ ID NO. 3.

28. The adduct of claim 25, said switch control ligand sequence being selected from the group consisting of SEQ ID NO. 4, SEQ ID NO. 5, and combinations thereof.

29. The adduct of claim 25, said C-lobe residues including F.

30. The adduct of claim 21, said kinase selected from the group consisting of the consensus wild type sequence and disease polymorphs thereof.

31. The adduct of claim 21 said molecule having the structure of the compound of claim 1.

32. The method of claim 5, said molecule further binding to other sites on said kinase.